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THE BIOLOGICAL FUNCTION OF INTERACTING 
PARTNERS OF ZXD FAMILY PROTEINS 
 
Rupa V. Koneni 
 
Abstract 
 We have identified several protein-protein interactions amongst the members of 
the zinc finger, X-linked (ZXD) family of proteins (ZXDA, ZXDB, ZXDC and ZXDC2) 
that have important roles in the regulation of major histocompatibility complex class II 
and several myeloid-specific genes.  The ZXDC and ZXDA proteins share significant 
nucleotide sequence homology and each contain ten C2H2 zinc fingers and a transcription 
activation domain.  In addition, ZXDC has a C-terminal region that is necessary to 
interact with a key cofactor, CIITA (Class II transactivator) and activate Major 
histocompatibility complex class II and class I (MHC II and MHC I respectively) genes.   
 In chapter II we demonstrate that the ZXDC and ZXDA proteins can self-
associate, as well as, hetero-associate.  Moreover, in vitro studies in our lab revealed that 
the association of ZXDC with ZXDA is necessary and self-association of neither protein 
was sufficient to interact with CIITA and thereby activate MHC II gene transcription.  In 
addition to CIITA, we found that ZXDC interacted with two other components of the 
regulatory factor X complex, namely, RFX5 and RFX-ANK (RFX having ankyrin 
repeats) which are components of the MHC II enhanceosome.  The RFX heterotrimeric 
complex consisting of RFX5, RFX-AP (RFX-associated protein), RFX-ANK binds to the 
viii 
 
conserved X1 box of MHC II promoter.  The necessity for RFX complex in MHC II gene 
regulation is underscored by bare lymphocyte syndrome, a genetic disorder which results 
from mutation in one of the RFX proteins.  Our results support for a role of ZXDC-
ZXDA heterocomplex to mediate interactions with components of the MHC II 
enhanceosome thereby enhancing the stability of the complex as a mechanism of 
activating MHC II gene transcription.   
 Interestingly, the ZXD family of proteins seems to have a broader role in gene 
regulation.  In chapter III we demonstrate that the ZXDC protein interacts and represses 
the transcriptional activities of two myeloid transcription factors, namely, purine box 
binding protein PU.1 and Growth factor independent-1 (Gfi-1).  The MYC gene promoter, 
a known target of Gfi-1, was also found to be bound by ZXDC protein.  These results 
suggest that ZXDC may affect PU.1 and Gfi-1 transcriptional activities and/or 
recruitment at their target gene promoters suggesting that it may have a functional role in 
the differentiation of myeloid progenitor cells into specific lineages.  We found that 
ZXDC enhanced PU.1 protein stability whose expression levels are critical for 
hematopoietic cell lineage decisions and development.  We also demonstrated that ZXDC 
activated the transcription of the early growth response-2 (EGR2) gene whose expression 
is associated with monocyte-specific gene expression and repression of granulocyte 
genes.  Our results strongly suggest that ZXDC, by affecting PU.1 and Gfi-1 recruitment 
and transcriptional activities at their target gene promoters, and by increasing Egr-2 
expression, has an important regulatory role in monopoiesis. 
 
 
 
ix 
 
TABLE OF CONTENTS 
 
ABSTRACT……………………………………………………........................ vii          
LIST OF FIGURES………………………………………………................. xi 
LIST OF TABLES .......................................................................................... xiv 
LIST OF ABBREVIATIONS………………………………………........... xv 
CHAPTER 
I. BACKGROUND AND INTRODUCTION    
 Major Histocompatibility Complex Class II genes: Structure  
 and Function............................................................................................. 1 
 Transcriptional Regulation of MHC II Genes........................................... 2 
 MHC II Enhanceosome..................................................................... 6 
 Class II Transactivator: Structure and Function......................................... 10 
 Role of ZXDC and ZXDA Proteins in MHC II Gene Regulation............. 13 
 C2H2 Zinc fingers in Protein-Protein Interactions...................................... 14 
 Role of Transcription Factors in Myeloid Development 
 and Leukemogenesis.................................................................................. 20 
 PU.1 and its Interacting Partners: Role in Myeloid Development 
 and Differentiation..................................................................................... 23 
 Growth Factor Independent-1 in neutrophil differentiation...................... 27 
 Dissertation Goals.......................................................................................31 
 
II. PROTEIN-PROTEIN INTERACTIONS OF ZXDC, 
x 
 
 ZXDA: ROLE IN MHC CLASS II GENE REGULATION 
 Abstract………………………………………………………………...... 33 
 Introduction…………………………………………………………........ 34 
 Materials and Methods…………………………………………………... 39 
 Results…………………………………………………………………… 43 
 Discussion……………………………………………………………….. 55 
 Literature Cited for Chapter II…………………………………………. 59 
 
III. THE INTERACTION OF THE ZXDC PROTEIN WITH  
 HEMATOPOIETIC TRANSCRIPTION FACTORS, 
 PU.1 AND GFI-1: A ROLE IN MYELOPOIESIS 
 Abstract.................................................................................................... 65 
Introduction.............................................................................................. 66 
 Materials and methods.............................................................................. 71 
 Results....................................................................................................... 79 
 Discussion................................................................................................. 103 
 Literature Cited for Chapter III................................................................. 108 
 
IV. DISCUSSION...................................................................................... 117 
 Literature Cited for Chapter IV ................................................................ 130 
 
GENERAL REFERENCES........................................................................... 140 
xi 
 
LIST OF FIGURES 
Figure 
1.1  Genetic organization of the distribution of MHC class II 
  genes on human chromosome  …………………………………… 3 
1.2  Structure of MHC II molecule  ..…………………………………... 4 
1.3  Antigen presentation for T-cell activation  ……………………….. 5 
1.4  Schematic representation of the conserved upstream sequences 
  in the promoter of MHC II genes ………………………………… 7 
1.5  Schematic representation of the MHC II enhanceosome ………… 9 
1.6  Schematic representation of the various domains of the  
  CIITA protein …………………………………………………….. 12 
1.7  Schematic representation of the domain structure of the 
  ZXDC protein …………………………………………………….. 15 
1.8  Schematic representation of the domain structure of the 
  ZXDA protein …………………………………………………….. 16 
1.9  Structure of a C2H2 type zinc finger ……………........................... 17 
1.10  Schematic representation of the domain structure of the 
  PU.1 protein and its interacting partners …………………………. 26 
1.11  Schematic representation of the domain structure of Growth 
  factor independent-1 ……………………………………………… 29 
1.12  Defects in neutrophil differentiation and development upon 
  loss of function mutations of key transcription factors ………….... 30 
 
xii 
 
2.1  Schematic representation of ZXDC, ZXDA, ZXDB  
  representing the regions of homology in various domains ………. . 37 
2.2  ZXDC and ZXDA proteins self-associate ………………………… 44 
2.3  Zinc fingers of ZXDA are necessary to interact with ZXDC …….. 46 
2.4  Zinc fingers of ZXDC are necessary to interact with ZXDA …….. 48 
2.5  ZXDC interacts with RFX5 protein ……………………………..... 50 
2.6  ZXDC co-immunoprecipitated with RFXANK ………………….. 52 
2.7  ZXDC does not interact with RFXAP ……………………………. 54 
3.1  A model for PU.1 and Gfi-1 mediated transcriptional 
  regulation of granulocyte and monocyte lineage commitment 
  and maturation ……………………………………………………. 69 
3.2  ZXDC and ZXDA co-immunoprecipitate with PU.1 ……………. 80 
3.3  Zinc fingers of ZXDC mediate interaction with PU.1 ……………. 82 
3.4  ZXDC interacts with the region of PU.1 containing the 
  activation domain …………………………………………………. 85 
3.5  ZXDC and ZXDA repressed PU.1 transcriptional activity ………. 87 
3.6  ZXDC has a role in PU.1 protein stabilization …………………… 90 
3.7  ZXDC and ZXDA co-immunoprecipitate with Gfi-1 ……………. 92 
3.8  Zinc fingers of ZXDC mediate ZXDC-Gfi-1 interaction ………… 94 
3.9  ZXDC repressed Gfi-1 transcriptional activity in a  
  dose-dependent manner …………………………………………... 96 
3.10  Chromatin immunoprecipitation (ChIP) analysis in HEK293 
  cells demonstrating the presence of ZXDC along with Gfi-1 
xiii 
 
  at the c-Myc locus ………………………………………………… 98 
3.11  ZXDC activates Egr-2 gene transcription ………………………… 100 
3.12  ZXDC enhanced Egr-2 and Egr-4 mRNA expression levels ……... 102  
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiv 
 
LIST OF TABLES 
 
Table 
1.1  Amino acid sequences of ten C2H2 type zinc fingers of  
  ZXDC protein …………………………………………………….. 19 
1.2  Examples of transcription factor mutations and their  
  effects in AML patients…………………………………………… 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
xv 
 
LIST OF ABBREVIATIONS 
APC    Antigen presenting cell 
AML    Acute myeloid leukemia 
AML1    Acute myeloid leukemia protein 1 
AMKL   Acute megakaryoblastic leukemia 
BSAP    B-cell specific activator protein 
BLSII    Bare lymphocyte syndrome type II 
CIITA    Class II transactivator 
CDKI    Cyclin dependent kinase inhibitor 
C/EBPα   CCAAT/ enhancer binding protein α 
C/EBPβ   CCAAT/enhancer binding protein β 
C/EBPє   CCAAT/enhancer binding protein є 
ChIP    Chromatin immunoprecipitation 
CMP    Common myeloid progenitor 
Co-IP    Co-immunoprecipitation 
CREB    Cyclic AMP responsive element binding protein 
CUS    Conserved upstream sequence 
DMEM   Dulbecco’s modified eagle’s medium 
EDTA    Ethylenediaminetetraacetic acid 
EGR    Early growth response proteins 
ETO    Eight 21 corepressor 
FAB    French American British system of classification 
FBS    Fetal bovine serum 
xvi 
 
FLT3    FMS related tyrosine kinase 3 
FOG    Friend of GATA 
GATA1   GATA binding protein 1 
GATA2   GATA binding protein 2 
G-CSF    Granulocyte colony stimulating factor 
G-CSFR   Granulocyte colony stimulating factor receptor 
Gfi-1    Growth factor independent-1 
GM-CSF   Granulocyte-monocyte colony stimulating factor 
GMP    Granulocyte monocyte progenitor 
GR    Glucocorticoid receptor 
HA    Haemaglutinin 
HDAC    Histone deacetylase 
HLA    Human leukocyte antigen 
HOX    Homeobox 
HSP90    Heat shock protein 90 
HSC    Hematopoietic stem cell 
IA    Iodoacetamide 
IB    Immunoblot 
ICSBP    Interferon consensus sequence binding protein 
IFNα    Interferon alpha 
IFNβ    Interferon beta 
IFNγ    Interferon gamma 
IP    Immunoprecipitation 
xvii 
 
IRF    Interferon regulatory factor 
ITD    Internal tandem duplication 
IL-2    Interleukin 2 
LMP    Lymphoid myeloid progenitor 
LRR    Leucine rich repeat 
MCSF    Macrophage colony stimulating factor 
MCSFR   Macrophage colony stimulating factor receptor 
MEP    Megakaryocyte erythroid progenitor 
MHC II/ MHC class II Major histocompatibility complex class II 
miRNA   Micro-RNA 
MLL    Mixed lineage leukemia 
MoMLV   Moloney murine leukemia virus 
MPP    Multipotential progenitor 
MYH11   Myosine heavy chain 11 
NEM    N-ethylmaleimide 
NF-κB    Nuclear factor kappa B 
PML    Promyelocytic leukemia 
PMSF    Phenyl methyl sulfonyl fluoride 
P/S/T    Proline/serine/threonine rich domain 
PU.1    Purine box binding protein coded by Spi-1 gene 
PVDF    Polyvinylidene difluoride 
RARα    Retinoic acid receptor α 
RFXANK   Regulatory factor X with ankyrin repeats 
xviii 
 
RFXAP   Regulatory factor X associated protein 
RUNX1   Runt related transcription factor 1 
SDS-PAGE   Sodium dodecyl sulphate polyacrylamide gel  
    electrophoresis 
SELEX   Systemic evolution of ligands by exponential enrichment 
SNAG    Snail/Gfi1 domain 
SPI1    Spleen focus forming virus (SFFV) proviral integration 
SUMO    Small ubiquitin like modifier 
TAD    Transcriptional activation domain 
TCR    T cell receptor 
TGFβ    Transforming growth factor β 
VDR    Vitamin D receptor 
WB    Western blot 
ZXDA    Zinc finger X linked duplicated family member A 
ZXDB    Zinc finger X linked duplicated family member B 
ZXDC    Zinc finger X linked duplicated family member C 
1 
 
 
 
CHAPTER I 
BACKGROUND AND INTRODUCTION 
Major histocompatibility complex class II genes - Structure and Function 
 The expression of major histocompatibility complex class II (MHC II) genes is 
important for adaptive immune response.  MHC II molecules are cell surface 
glycoproteins that are expressed on professional antigen presenting cells (APC) such as B 
cells, dendritic cells, macrophages and thymic epithelial cells and are inducible by 
interferon gamma (IFNγ) on most other cell types.  These proteins are encoded on the 
short arm of chromosome 6 (6p.21.32) (Trowsdale, 1993) and the genes encoding these 
proteins are called Human leukocyte antigens (HLA).  HLA-DR, HLA-DP and HLA-DQ 
are the three MHC II isotypes in humans.  Fig. 1.1 depicts a schematic representation of 
the organization of MHC II genes on the short arm of chromosome 6.   
 MHC class II is a heterodimer composed of an alpha and a beta chain.  The C-
terminal transmembrane domains of the alpha and beta chains anchor to the cell 
membrane and their N-terminal regions form a cleft like structure on the cell surface to 
present antigenic peptides to the T cell receptor (TCR) of CD4
+
 T helper cells (Fig. 1.2).  
Based on the MHC II peptide-TCR interaction (Fig. 1.3), it will result in either positive or 
2 
negative selection of the CD4
+
 T cell population that will determine the selection of the 
TCR of the mature CD4
+
 T cell population (Viret and Janeway, Jr., 1999).  This MHC II 
peptide-TCR interaction is necessary for initiation, maintenance and regulation of antigen 
specific immune response (Cresswell, 1994; Waldburger et al., 2000).  The life span of 
the CD4
+
 T cell population in the periphery is also dependent on this interaction (Viret 
and Janeway, Jr., 1999). 
 Tight regulation of MHC II gene expression is critical.  For example, lack of 
MHC II expression leads to a severe immune deficient condition called Bare Lymphocyte 
Syndrome type II (BLS II) (Touraine and Marseglia, 1992), whereas, over-expression of 
MHC II genes can result in autoimmunity caused by their inappropriate expression 
(Bottazzo et al., 1986a; Bottazzo et al., 1986b). 
Transcriptional regulation of MHC II genes 
 MHC II genes are tightly regulated at the transcriptional level (Mach et al., 1996; 
Benoist et al., 1990; Glimcher et al., 1992; Ting et al., 1993; Boss et al., 1997).  These 
genes are expressed either in a constitutive or inducible manner (Mach et al., 1996; 
Benoist et al., 1990; Glimcher et al., 1992; Ting et al., 1993; Boss et al., 1997).  
Constitutive expression of MHC II genes occurs on professional antigen presenting cells, 
namely, B lymphocytes, macrophages and dendritic cells, whereas, they can be induced 
in most cell types by IFNγ (Drozina et al., 2005).  However, transforming growth factor β 
(TGF β), interleukin-1 (IL-1), interferon α (IFN α) inhibit MHC II expression by IFNγ 
(reviewed in Waldburger et al., 2000).  
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FIGURE 1.1 Genetic organization of the distribution of MHC class II genes on 
human chromosome 6:  The distribution of MHC II gene isotypes, HLA-DP, DQ, DR 
on human chromosome 6 is shown above.  Each isotype has distinct α and β encoding 
genes.  LMP/TAP genes code for proteins necessary for processing antigen and HLA-
DM gene code for proteins necessary for antigen presentation of MHC class II molecules. 
 
 
 
 
 
 
 
β α α α αβ β β1 β2
DP           DM        LMP/TAP        DQ            DR  
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FIGURE 1.2 Structure of MHC II molecule:  MHC II molecules are cell surface 
glycoproteins that are expressed on the surface of professional antigen presenting cells.  
The protein consisting of an alpha and beta subunit forms a cleft like structure on the cell 
surface for peptide binding and antigen presentation. 
 
 
 
 
 
 
Peptide binding groove
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FIGURE 1.3 Antigen presentation for T-cell activation:  In order for T cells to be 
activated, they must recognize the antigen presented by the antigen presenting cell 
(APC).  The APC processes and presents peptide antigens to the T-cell receptor (TCR) of 
the helper T cell.  Co stimulation usually involves additional proteins like B7 and CD28 
on the surface of APC and T-helper cells respectively (reviewed in Peggs et al., 2008).  
The MHC II peptide complex-TCR interaction is necessary for initiation, maintenance 
and regulation of immune responses. 
 
 
Activated macrophage
T-helper cell 
(Antigen presenting cell)
T-cell receptor
Presented antigen
B7
CD28
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 A set of conserved promoter elements (namely, W/S, X1, X2 and Y boxes in a 5‟ 
to 3‟ orientation; Fig. 1.4) are located with in 150 bps upstream of the transcription start 
site that are necessary and sufficient for both constitutive and inducible expression of 
MHC II proteins.  The position, orientation and spacing among the conserved cis-
elements are critical for MHC II expression (reviewed in Waldburger et al., 2000).  
Similar arrangement of cis-elements is seen in the promoters of invariant chain (Ii) and 
HLA-DM genes (Ting et al., 1997; Westerheide et al., 1997; Brown et al., 1991; Brown 
et al., 1993; Tai et al., 1999) which code for proteins necessary for intracellular 
trafficking and peptide loading of MHC II molecules (Busch et al., 1996; Cresswell et al., 
1996).  Recently, additional X-box like sequences in MHC II region were identified that 
function as locus control regions (Gomez et al., 2005). 
MHC II enhanceosome 
 The promoter of MHC II genes consist of a set of conserved upstream sequences 
(CUS), namely, W/S, X1, X2 and Y boxes (5‟ to 3‟ orientation).  These promoter 
elements are necessary and sufficient for the transcriptional regulation and expression of 
these genes in a constitutive and inducible manner (Benoist et al., 1990; Glimcher et al., 
1992).  The position and orientation of these promoter elements with respect to each 
other is critical for their function.  A set of DNA binding proteins, namely, regulatory 
factor X (RFX) heterotrimeric complex, cyclic AMP response element binding (CREB) 
protein and nuclear factor Y (NFY) complex bind to the conserved X1, X2 and Y boxes 
respectively.  The RFX complex, composed of RFX5 (Steimle et al., 1995), RFXAP 
(RFX associated protein) (Villard et al., 1997) and RFXANK (RFX with ankyrin repeats)    
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FIGURE 1.4 Schematic representation of the conserved upstream sequences in the 
promoter of MHC II genes:  The W/S, X1, X2 and Y box represent the conserved 
promoter elements located within 150 bps upstream of the transcription start site of the 
MHC II promoter.  The orientation and spacing among these elements with respect to 
each other is critical for proper MHC II gene regulation.  These elements are necessary 
and sufficient for both constitutive and inducible expression of MHC II genes. 
 
 
 
 
 
 
 
Promoter elements
W/S box X1box X2box Y box
MHC class II 
gene transcription
+1-150
8 
(Masternak et al., 1998) binds to the X1 box as a heterotrimeric complex (DeSandro et 
al., 2000).  The X2 box is bound by cyclic AMP responsive element binding (CREB) 
protein (Moreno et al., 1999).  The NFY complex composed of NFY-A, NFY-B and 
NFY-C proteins binds to the Y box (Mantovani, 1999).  The W/S box is critical for MHC 
II expression, but the identity of the protein or complex that binds there is not yet known 
(Kara and Glimcher, 1991).  These DNA binding proteins are ubiquitously distributed & 
though their expression is necessary, it is not sufficient for MHC II expression.   
 The expression of MHC II genes in a given cell type is mainly determined by a 
transcriptional cofactor named class II transactivator (CIITA; Steimle et al., 1993).  The 
CIITA protein does not bind DNA directly; instead it is recruited to MHC II promoter 
through co-operative interactions with the DNA bound factors (Masternak et al., 2000).  
CIITA also recruits chromatin remodeling factors and histone modifying enzymes and 
through synergistic interactions with the DNA bound factors forms a three-dimensional 
higher order complex which is termed the MHC II enhanceosome (Masternak et al., 
2000; Waldburger et al., 2000; Jabrane-Ferrat et al., 2003; Spilianakis et al., 2003).  Fig. 
1.5 demonstrates a schematic representation of the components of the MHC II 
enhanceosome. 
 Enhanceosomes are higher order complexes and are held through multiple 
protein-protein and protein-DNA interactions that function in a co-operative manner to 
activate target genes.  Specific enhanceosomes regulate several other eukaryotic genes, 
for example, Interferon β (IFN β), T-cell receptor α chain and interleukin-6 (IL-6) 
(Merika and Thanos, 2001).  In the case of MHC II enhanceosome, there exist 
cooperative interactions between the DNA bound factors (Westerheide and Boss, 1999; 
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FIGURE 1.5 Schematic representation of the MHC II enhanceosome:  This figure 
demonstrates a schematic representation of various cis-elements and trans-acting factors 
that constitute components of the MHC II enhanceosome.  The RFX heterotrimeric 
complex consisting of RFX5, RFX-AP and RFX-ANK binds to the X1 box, NFY 
complex composed of NFY-A, B, C binds to the Y box, whereas, CREB protein binds to 
the X2 box.  The factor binding to the W/S box is critical for the recruitment of CIITA, 
though the identity of this protein is not known.  The CIITA protein does not bind DNA 
directly and is recruited to the MHC II promoter by the DNA bound factors. 
  
 
Promoter elements
W box X1 box X2box Y box
MHC class II 
gene transcription
CREB
RFX
CIITA
NFY
+1-150
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Caretti et al., 2000).  The individual protein-protein or protein-DNA interactions are 
weak, but, multiple interactions are capable of recruiting the key transcriptional co-
activator, CIITA (Masternak et al., 2000).  There are several mechanisms of 
enhanceosome dependent transcriptional synergy.  Some of these include modification of 
chromatin structure for the recruitment of preinitiation complex, enabling nucleosome 
modification and enhancing the stability of enhanceosome (reviewed in Merika and 
Thanos, 2001; Carey, 1998).   
Class II transactivator - Structure and Function 
 CIITA belongs to the CATERPILLER family of proteins which is so named for 
the various conserved domains-namely CARD domain, transcriptional enhancer, purine 
binding, pyrin domain and lots of leucine rich repeats (Harton et al., 2002).  It is a large 
protein consisting of 1130 amino acids.  Fig. 1.6 is a schematic representation of the 
various domains of the CIITA protein.  The N-terminal region (amino acids 25-145) is 
rich in acidic amino acids and functions as a transcription activation domain (TAD; Riley 
et al., 1995).  Next to this, is a region rich in proline, serine, threonine (P/S/T) residues.  
Phosphorylation of the P/S/T domain is required for oligomerization and accumulation of 
the protein (Tosi et al., 2002).  Following the P/S/T domain are three GTP binding motifs 
that are necessary for nuclear import and self-association (Chin et al., 1997; Harton et al., 
1999; Linhoff et al., 2001; Raval et al., 2003).  The C-terminal portion of the protein 
(amino acids 957-1130) has several leucine rich repeats which have a role in protein-
protein interactions, nuclear translocation and self-association of CIITA protein (Hake et 
al., 2000; Kretsovali et al., 2001; Sisk et al., 2001; Towey et al., 2002; Sisk et al., 2003; 
Linhoff et al., 2001; Harton et al., 2002).  CIITA plays an important role in MHC II 
11 
enhanceosome assembly.  In addition to DNA bound factors, CIITA also interacts with 
subunits of general transcription machinery (hTAFII32, hTAFII70, hTAFII250; Fontes et 
al., 1997; Mahanta et al., 1997) and chromatin modifying enzymes (CBP, P300, pCAF; 
Kretsovali et al., 1998; Fontes et al., 1999; Spilianakis et al., 2000) that have important 
roles in activating MHC II gene transcription.  In order to better understand the molecular 
mechanisms of CIITA mediated MHC II gene activation, our lab performed yeast-two 
hybrid assay of human spleen cDNA library with the C-terminal leucine rich repeats of 
the CIITA protein, as one of its important roles is to mediate protein-protein interactions 
(Kobe and Kajava, 2001).  Of the several positive clones, one was a poorly characterized 
cDNA coding for a novel zinc finger protein, named as Zinc finger, X-linked, duplicated 
family member C (ZXDC).  ZXDC protein has ten C2H2 type zinc fingers towards the 
amino terminus, followed by a transcription activation domain and a C-terminal region 
that mediates interaction with CIITA (Fig. 1.7; Alkandari et al., 2007a).  ZXDC protein 
was so named because of its amino acid sequence homology with two other zinc finger 
proteins, namely, Zinc finger, X-linked, duplicated family members A and B (ZXDA and 
ZXDB respectively; Fig. 1.8 demonstrates a schematic representation of the domain 
structure of the ZXDA protein).  Studies in our lab demonstrated that the ZXDC and 
ZXDA proteins cooperated with CIITA in the activation of MHC II gene transcription, 
whereas, knockdown of ZXDC or ZXDA reduced the ability of CIITA to activate MHC 
II genes without affecting CIITA expression.      
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FIGURE 1.6 Schematic representation of the various domains of the CIITA protein:  
The CIITA is a 1130 amino acid protein composed of an N-terminal activation domain 
(amino acids 25-145) rich in acidic amino acids, followed by Proline/Serine/Threonine 
(P/S/T) domain, GTP binding domain (amino acids 336-702) and C-terminal leucine rich 
repeat region (amino acids 957-1130). 
 
 
 
 
 
 
 
 
 
1    25                      145  169               322         336           702                             957                                1130
TAD
P/S/T 
domain
GTP binding 
domain
Leucine rich 
repeats
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Role of ZXDC and ZXDA proteins in MHC II gene regulation 
 Our lab performed yeast-two hybrid assay using the CIITA C-terminal 807 amino 
acid fragment as bait and identified a novel protein named Zinc finger, X linked, 
duplicated family member C (ZXDC).  The ZXDC protein contained ten multiple 
adjacent C2H2 type zinc fingers followed by transcription activation domain (TAD) and a 
C-terminal CIITA binding region.  Fig. 1.7 depicts a schematic representation of the 
various domains of the ZXDC protein.  Studies in our lab demonstrated that ZXDC 
cooperated with CIITA to activate MHC II and MHC I genes, whereas, knock-down of 
ZXDC reduced MHC II expression by CIITA (Al-Kandari et al., 2007a).  In the same 
report, the presence of ZXDC at MHC II gene promoter in Raji cells, a B cell line that 
constitutively expresses MHC II genes was shown.  ZXDC protein was so named because 
of its amino acid sequence homology with two other zinc finger proteins, namely, Zinc 
finger, X-linked, duplicated family members A and B (ZXDA and ZXDB respectively; 
Fig. 1.8 demonstrates a schematic representation of the domain structure of the ZXDA 
protein).  The ZXDA and ZXDB proteins were identified during X-inactivation studies 
(Greig et al., 1993).  Studies in our lab demonstrated that ZXDA also cooperated with 
CIITA resulting in synergistic activation of MHC II genes (Al-Kandari et al., 2000b).  
This was an interesting observation since ZXDA lacked the CIITA binding region, but 
still cooperated with CIITA suggesting that other interacting partners could mediate 
ZXDA-CIITA interaction.  In the same report, it was demonstrated that the ZXDC and 
ZXDA proteins can self-associate as well as interact with each other and „in vitro‟ studies 
demonstrated that only the ZXDC-ZXDA hetero-complex but neither protein by itself 
were found to interact with CIITA.  Supporting this, silencing the expression of ZXDC or 
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ZXDA reduced MHC II expression by CIITA similar to that of knock-down of both 
ZXDC and ZXDA demonstrating their cooperative role in MHC II gene activation (Al-
Kandari et al., 2000b).  In addition, ZXDC protein was found to be present at the MHC II 
promoter in HeLa cells prior to and after IFNγ treatment (Alkandari et al., 2000b). 
C2H2 zinc fingers in protein-protein interactions 
 Zinc fingers were first identified as conserved motifs present in the DNA binding 
protein TFIIIA. A C2H2 zinc finger is also called the TFIIIA or Kruppel-like finger and 
consists of 20-30 amino acids with a secondary structure formed by tetrahedral binding of 
Zn
2+
 to two cysteine and two histidine residues (Klug and Schwabe, 1995; Pabo et al., 
2001; Laity et al., 2001).  It consists of two β strands and an α helix and is generally 
described as X2CX2-4CX12HX2-8H where „X‟ is any amino acid and the numbers represent 
the spacing among the conserved residues (Fig 1.9). The structure of zinc fingers mainly 
depends on the nature and spacing between the conserved amino acid residues that bind 
to the Zn
2+
 (Mackay et al., 1998).  In classical zinc fingers, the zinc atom is coordinated 
in either a Cys-Cys-His-His or Cis-Cis-His-Cys manner.  The C2H2 zinc finger proteins 
are the largest among the zinc finger family of proteins and were found to have roles in 
development, differentiation and tumor suppression.   
 Based on the number and the arrangement of C2H2 zinc fingers in proteins, they 
are classified into four groups (a) single C2H2 (b) triple C2H2 (c) multiple adjacent C2H2 
and (d) separated-paired C2H2 zinc finger proteins (Iuchi et al., 2001).  The multiple zinc 
fingers are generally arranged in tandem with short peptide sequences between them 
called “linkers”.  The ZXD family proteins, ZXDC, ZXDA and ZXDB proteins have ten 
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FIGURE 1.7 Schematic representation of the domain structure of the ZXDC 
protein:  ZXDC is a 858 amino acid protein consisting of ten C2H2 type zinc fingers 
towards the N-terminus (between amino acids 177-475), followed by transcriptional 
activation domain (TAD; amino acids 578-688) and a C-terminal domain that is 
necessary for interaction with the CIITA protein (amino acids 688-858). 
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FIGURE 1.8 Schematic representation of the domain structure of the ZXDA 
protein:  ZXDA is a 799 amino acid protein consisting of ten C2H2 type zinc fingers 
towards the N-terminus of the protein (between amino acids 267-572) and a 
transcriptional activation domain (TAD; amino acids 699-799) at the C-terminus. 
 
 
 
 
 
 
 
 
 
 
 
1 799267 572
699
TADZinc fingers
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FIGURE 1.9 Structure of a C2H2 type zinc finger:  A C2H2 zinc finger consists of two 
β strands and an α helix and is made of 20-30 amino acids with a secondary structure 
formed by tetrahedral binding of Zn
2+
 to two cysteine and two histidine residues.  It is 
generally represented as X2CX2-4CX12HX2-8H where X is any amino acid and the 
numbers represent spacing among the conserved residues.  The structure of a zinc finger 
mainly depends on the type and spacing among the conserved residues that bind to the 
Zn
2+
 (Ref: Gamsjaeger R et al., 2007). 
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multiple adjacent C2H2 type zinc fingers, whereas, the ZXDC2 protein, an mRNA variant 
of ZXDC, lacks the first three fingers that are conserved in other members of the family.  
Table 1.1 shows the amino acid sequences of the ten zinc fingers in ZXDC protein.   
 Although zinc fingers (ZnFs) are majorly known to have roles in DNA binding, 
there are several examples of zinc finger proteins that have functional roles mediated by 
protein-protein interactions (Mackay et al., 1998; Sun et al., 1996; Morgan et al., 1997; 
Merika et al., 1995; Tsai et al., 1998) and by RNA binding (Brown, 2005; Hall, 2005; 
Lee et al., 2006; Lu et al., 2003).  Many zinc finger proteins undergo homo- and/or 
hetero-dimerization by hydrophobic interactions or by finger-finger binding.  
Dimerization of these proteins was found to modulate their DNA binding activity and to 
regulate the expression of target genes.  In addition, the relative levels of homo- and 
hetero-dimers available and the expression levels of the proteins involved modulates their 
activity that result in important biological effects (Morgan et al., 1997).  Also, in many 
proteins having multiple zinc fingers, some zinc fingers mediate DNA binding, whereas, 
others are involved in selective protein-protein interactions (Kelley et al., 1998; Tsai et 
al., 1998; Matsuzawa-Watanabe et al., 2003) which play a role in several regulatory 
functions.   
 An example of the multi-functional nature of zinc fingers is the friend of GATA-1 
(FOG) protein, a zinc finger transcription factor containing nine classical zinc fingers.  
Five of these fingers mediate protein-protein interaction with the N-terminal GATA type 
ZnF of the transcription factor GATA-1.  The recruitment of FOG by GATA-1 at GATA-
1 target gene promoters is found to be necessary for erythro- and megakaryopoiesis in 
mammals (Tsang et al., 1998).  In another example, transcription factors of the Ikaros 
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TABLE 1.1 Amino acid sequences of ten C2H2 type zinc fingers of ZXDC protein:  
The amino acid sequences of ten Cys-Cys:His-His zinc fingers of the ZXDC protein is 
shown in the table above (Alkandari et al., 2007a) 
 
 
 
 
 
 
 
177CPEPQCALAFAKKHQLKVHLLTH
210CPLEGCGWAFTTSYKLKRHLQSH
240CPVGGCGKKFTTVYNLKAHMKGH
270CEV--CAERFPTHAKLSSHQRSH
299CDFPGCEKTFITVSALFSHNRAH
330CSFPGCSKQYDKACRLKIHLRSH
360CDSDSCGWTFTSMSKLLRHRRKH
389CPVEGCGKSFTRAEHLKGHSITH
419CPVEGCCARFSARSSLYIHSKKH
452CPVSTCNRLFTSKHSMKAHMVRQH
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family have two clusters of zinc fingers - one at the N-terminus and another at the C-
terminus.  The N-terminal cluster was found to have a role in DNA binding and the C-
terminal cluster mediates interactions with itself, as well as, with other members of the 
family and these interactions were found to have a central role in lymphoid development 
(Kelley et al., 1998; McCarty et al., 2003).  However, it should be noted that direct gene 
regulation mediated by zinc fingers is not the only regulatory mechanism by zinc finger 
proteins.  There are examples of zinc finger proteins that have biological roles that are 
mediated by protein-protein interactions.  An example is the Escherichia coli heat shock 
protein, DnaJ (contains two CCCC zinc fingers) that binds to unfolded proteins and helps 
in their folding in the cell (reviewed in Mackay et al., 1998). 
Role of transcription factors in myeloid development and leukemogenesis 
Transcription factors play a very important role in hematopoiesis (Blau, 1991; 
Shivdasani, 1996; Orkin, 1995).  The differentiation and development of hematopoietic 
stem cells into mature myeloid cells, namely, granulocytes and monocytes is known as 
myelopoiesis.  Transcription factors play an important role in the differentiation of 
hematopoietic stem cells into multipotential progenitors (MPP; granulocyte-monocyte 
progenitors [GMP], in this case) which in turn give raise to mature granulocytes or 
monocytes (Friedman, 2007).  The MPP have lost complete self-renewal activity but 
express receptors for certain growth factors and have the potential to develop into 
specific hematopoietic cell lineages that can develop into mature blood cells.  Our study 
focuses on transcription factors involved in myeloid development and differentiation. 
The key role of transcription factors in myeloid differentiation and 
leukemogenesis has been reviewed vastly in the past few years (Friedman, 2007; 
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Rosenbauer and Tenen, 2007; Tenen, 2003; Laslo et al., 2006).  Studies have 
demonstrated that cross-talk among several key transcription factors, their expression and 
activity is critical for determining hematopoietic cell lineage decisions and differentiation 
(Orkin, 2000).  Such regulatory mechanisms are important for normal myeloid 
development.  For example, Acute myeloid leukemia (AML) is a condition in which 
there is a block in the myeloid differentiation process resulting in uncontrolled 
proliferation of immature myeloid progenitors.  One of the major causes of this group of 
myeloid leukemias is mutation or dysregulation of certain key transcription factors 
involved in myeloid development and differentiation.  Some examples of transcription 
factor mutations in patients with AML are listed in table 1.2.  Identification and 
characterization of these factors and understanding their regulatory roles is very 
important for the discovery of novel therapeutic targets for intervention for the treatment 
of various types of cancers (Tenen, 2003). 
 In the determination of hematopoietic cell lineage decisions, several external (eg. 
growth factors, stroma) or internal factors or both may play a role (Metcalf, 1993; 
Roberts, 1988; Fairbairn, 1993; Just, 1993).  In either or both cases, the interplay among 
several cell-specific and ubiquitous transcription factors (which mostly results in the 
expression of growth factors or their receptors) and the net result of this cross-talk seem 
to play a crucial role for determining hematopoietic cell fates (Tenen et al., 1997).  In 
addition, several chromosomal rearrangements in different types of myeloid leukemias 
are at sites encoding transcription factors (Rabbitts et al., 1994), knock-out of key  
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Table 1.2 Examples of transcription factor mutations and their effects in AML 
patients:  The table above lists transcription factors that are often mutated and their 
effects in patients with acute myeloid leukemia (AML).  AMKL: acute megakaryoblastic 
leukemia; CBFβ: core binding factor β; C/EBPα: CCAAT/ enhancer binding protein α; 
FAB: French-American-British classification of AML that is based on the assessment of 
the stage of differentiation of blasts; FLT3: FMS-related tyrosine kinase 3; GATA1: 
GATA binding protein 1; HOX: homeobox; ITD: internal tandem duplication; MLL: 
mixed lineage leukemia; MYH11: myosin heavy chain 11; PML: promyelocytic 
leukemia; PU.1: transcription factor encoded by Spi-1; RARα: retinoic acid receptor α; 
RUNX1: runt-related transcription factor 1.  References: Miyoshi et al., 1991; Liu et al., 
1993; de The et al., 1990; Chang et al., 1992; Goddard et al., 1991; Kakizuka et al., 1991; 
Alcalay et al., 1991; Pandolfi et al., 1991; Ayton et al., 2001; Nerlov et al., 2004; 
Crispino et al., 2005; Cilloni et al., 2003; Wechsler et al., 2002; Crispino et al., 2005; 
Osato et al., 1999.  Table 1.2 has been taken from a review article written by Rosenbauer 
and Tenen, 2007. 
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transcription factors in animal models resulted in a block of myeloid cell differentiation 
(Zhang et al., 1997) and several of the genes that determine the differentiation steps 
encode transcription factors (Rosenbauer and Tenen, 2007).  Taken together, studies 
demonstrate for the critical role of transcription factors at different stages during myeloid 
development and differentiation.   
PU.1 and its interacting partners - Role in myeloid development and differentiation 
 PU.1 is a product of spleen focus forming virus (SFFV) proviral integration site 1 
(Spi1) oncogene whose expression is enhanced in murine erythroleukemia (Klemsz et al., 
1990; Moreau-Gachelin et al, 1988; Paul et al., 1991).  Deregulation of PU.1 results in an 
increase in erythroid self-renewal capacity resulting in a block in differentiation.  PU.1 is 
mainly expressed in monocytes, B lymphocytes, early T lymphocytes and granulocytes 
(Galson et al., 1993; Hromas et al., 1993).  It belongs to the Ets family of transcription 
factors and recognizes a purine rich core sequence (5‟ GAGGAA 3‟; PU box & hence the 
name) to regulate target genes (Klemsz et al., 1990).  It has been demonstrated that the 
expression levels of PU.1 are important in the determination of hematopoietic cell 
lineages, for example, high levels of PU.1 induce monocytic differentiation, whereas, low 
levels favor granulocyte development (Dahl et al., 2003; Laslo et al., 2006).  On the other 
hand, PU.1-/- mice die at late gestational stage and the embryos show a defect in the 
development of monocytes, lymphocytes and granulocytes (Scott et al., 1994). 
 The transcription factor PU.1 is a 272 amino acid protein with an N-terminal 
activation domain and C-terminal DNA binding Ets domain (Fig. 1.10).  The activation 
domain region is known to interact with several regulatory proteins (Hagemeier et al., 
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1993; Klemsz et al., 1990; Klemsz et al., 1996), whereas, the DNA binding domain is a 
winged helix-turn-helix motif that recognizes the PU.1 core sequence to regulate target 
genes (Kodandapani et al., 1996).  Figure 1.10 depicts a schematic representation of 
various domains of the PU.1 protein along with their interacting partners (reviewed in 
Tenen, 2003). 
 Several myeloid target genes are activated by PU.1.  These include activation of 
macrophage colony stimulating factor (M-CSF) receptor (Zhang et al., 1994; Reddy et 
al., 1994), granulocyte-macrophage colony stimulating factor (GM-CSF) receptor α 
(Hohaus et al., 1995) and granulocyte colony stimulating factor receptor (G-CSF) 
receptor promoters (Smith et al., 1996).  In addition, PU.1 regulates most of the genes 
involved in the development of multipotential myeloid progenitors into myeloid lineages 
and for their further differentiation into mature blood cells (DeKoter et al., 1998; 
Anderson et al., 1999).  Hence, PU.1 is considered the “master regulator” of 
myelopoiesis.  Interestingly, PU.1 is also autoregulated (Okuno et al., 2005) like several 
other hematopoietic transcription factors and such regulation was found to be necessary 
for their irreversible differentiation and commitment process. 
 Hematopoietic cell lineages are determined by cell-type specific and stage 
specific expression of transcription factors which are regulated at either transcriptional 
level, post-transcriptional level and/or through selective protein-protein interactions 
(Rosenbauer and Tenen, 2007).  First, regulation of transcription factors at the 
transcriptional level may include a complex set of cis-regulatory elements and trans-
acting factors, for example, AML1 (also called RUNX1) binds to the upstream regulatory 
sequences of SPI1 and regulates PU.1 expression both positively and negatively in a 
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lineage specific manner (Huang et al., 2008).  Second, an example for regulation at the 
post-transcriptional level is the C/EBPα mRNA which gives raise to a 42 kDa protein and 
by the use of an alternate translation initiation site gives raise to a 30 kDa dominant 
negative isoform.  The relative levels of these two isoforms determine the function of 
C/EBPα protein (Calkhoven et al., 2000).  In addition, phosphorylation of C/EBPα on 
serine 21 results in C/EBPα inactivation that occurs during macrophage differentiation 
(Ross et al., 2004), whereas, phosphorylation of serine 248 of C/EBPα results in 
enhanced binding of this protein to G-CSFR promoter promoting granulocytic 
differentiation (Behre et al., 2002).  Third, there are several examples for the regulation 
of hematopoietic transcription factors through protein-protein interactions which result in 
either co-operative or antagonistic effects that is essential for their optimal activity and 
tight regulation.  Examples of such interacting partners for PU.1 include GATA binding 
protein 1 (GATA1; Shivdasani et al., 1996; Orkin et al., 2000), TBP (TATA binding 
protein; Hagemeier et al., 1993), CCAAT/enhancer binding protein α (C/EBPα; Reddy et 
al., 2002), Growth factor independence-1 (GFI-1; Dahl et al., 2007), B-cell specific 
activator protein (BSAP; Maitra and Atchison, 2000), Interferon regulatory factor-8 (IRF-
8; Tsujimura et al., 2002) and Ski (Ueki et al., 2008).  Protein-protein interactions mainly 
result in either cooperative or antagonistic effects that are necessary to create imbalances 
in gene expression program for the development and differentiation of an immature 
multipotential progenitor into a specific cell lineage type. 
 
 
26 
 
 
 
 
 
 
Note: PU.1 also interacts with HMGI/Y, SSRP, MKP1, CBP.  But, the binding sites are 
not yet mapped. 
FIGURE 1.10 Schematic representation of the domain structure of the PU.1 protein 
and its interacting partners: PU.1 protein is composed of 272 amino acids consisting of 
N-terminal transcription activation domain (TAD; amino acids 1-119), followed by a 
region rich in Proline, Serine, Threonine residues (PEST; amino acids 119-160) and a C-
terminal Ets domain (between amino acids 160-245) that is necessary for DNA binding.  
The interaction of PU.1 with several hematopoietic transcription factors has been 
mapped. The TAD of the protein interacts with the general transcription factors, TFIID, 
TBP; GATA binding proteins, GATA1, GATA2, Glucocorticoid receptor (GR) and the 
heat shock protein (HSP90).  The PEST domain of the protein interacts with the 
Interferon regulatory factor (IRF) family, Interferon consensus sequence binding protein 
(ICSBP). The C-terminal Ets domain of the protein interacts with c-Jun, GATA1, 
GATA2, CCAAT enhancer binding proteins (C/EBPα, C/EBPβ), acute myeloid leukemia 
protein 1 (AML1).  References: Reddy et al., 2002; Dahl et al., 2007; Huang et al., 2007; 
Rekhtman et al., 1999; Vangala et al., 2003; Bassuk and Leiden , 1995; Aittomaki et al., 
2004; Gauthier et al., 1993; Wara-aswapati et al., 1999.  
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Growth factor independent-1 in neutrophil differentiation 
 Growth factor independent-1 (GFI-1) was identified as the site of Moloney 
murine leukemia viral (MoMLV) integration resulting in its over-expression and causing 
interleukin-2 (IL-2) growth independence in T cell lines (Gilks et al., 1993; Akagi et al., 
2004; Zornig et al., 1996).  GFI-1 is a transcriptional repressor that is indispensible for 
neutrophil differentiation and maturation (Hock et al., 2003).  GFI-1 is mainly expressed 
in common lymphoid progenitor, developing B and T lymphocytes, hematopoietic stem 
cells, granulocyte-monocyte progenitor and mature granulocytes (Zeng et al., 2004; 
Yucel et al., 2004).  Gfi1-/- mice show a defect in neutrophil differentiation 
demonstrating proliferation of immature myeloid progenitors that share characteristics of 
both macrophages (Mac
+
) and neutrophils (Gr1
+
) (Hock et al., 2003; Karsunky et al., 
2002).  In addition, these mice were highly susceptible to infections from gram-positive 
bacteria.  Studies have also shown that GFI-1 not only promotes neutrophil development 
and differentiation, but also antagonizes macrophage specific genes (Dahl et al., 2007).  
For example, GFI-1 interacts with PU.1 and represses its transcriptional activity resulting 
in the inhibition of expression of macrophage specific genes (Dahl et al., 2007; Hock et 
al., 2006).  A mutation in the GFI1 gene that inhibited GFI-1 transcriptional repression 
activity was identified in patients with a type of chronic neutropenia (Person et al., 2003).  
Another important role of GFI-1 is to maintain hematopoietic stem cell self-renewal 
capacity (Hock et al., 2004; Zeng et al., 2004). 
 GFI-1 is a 55kDa nuclear protein that contains an N-terminal SNAG repressor 
domain and six C2H2 type zinc fingers at the C-terminus (Zweidler-McKay et al., 1996; 
Grimes et al., 1996; Gilks et al., 1993).  Schematic representation of the various domains 
28 
of GFI-1 protein is shown in Fig. 1.11.  GFI-1 recognizes a DNA core sequence “AATC” 
to repress target genes and is a position and orientation independent transcriptional 
repressor.  It has been identified that the repressive effect of this protein is through 
recruitment of histone deacetylases (HDACs), G9a histone lysine methyl transferase 
and/or eight 21 corepressor (ETO) (Montoya-Durango et al., 2008; McGhee et al., 2003). 
 The development of mature neutrophils occurs in a step-wise manner through 
gene regulation and characteristic granules that determine their function (Borregaard et 
al., 2001).  The promyelocyte stage is characterized by the expression of 
myeloperoxidase and neutrophil elastase and the expression of primary granule proteins 
(peroxidase positive), with maturation to myelocyte stage secondary granules (peroxidase 
negative, lactoferrin positive) are synthesized and later tertiary granules (gelatinase 
containing) are produced at the metamyelocyte stage.  Figure 1.12 depicts the defects in 
neutrophil development and differentiation that occurs through loss of function mutations 
of critical transcription factors that are involved in this process (Hock and Orkin, 2006). 
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FIGURE 1.11 Schematic representation of the domain structure of Growth factor 
independent-1 (GFI-1):  GFI-1 is a 423 amino acid protein consisting of an amino-
terminal 20 amino acid SNAG repression domain necessary for transcriptional repression 
and six C2H2 type zinc fingers at the carboxy terminus necessary for DNA binding. 
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FIGURE 1.12 Defects in neutrophil differentiation and development upon loss of 
function mutations of key transcription factors:  Normal myeloid differentiation 
includes development of the granulocyte monocyte progenitors (GMP) from common 
myeloid progenitors (CMP).  The GMP further differentiates into myeloblast, 
promyelocyte, myelocyte, metamyelocytes and ultimately into mature neutrophil based 
on the synthesis of characteristic primary, secondary and tertiary granule proteins.  
Disruption of PU.1 results in early arrest before common myeloid progenitors.  Loss of 
C/EBPα results in a defect in the differentiation of granulocyte monocyte progenitors 
from common myeloid progenitors.  Loss of C/EBPє results in a defect in terminal 
neutrophil differentiation.  Disruption of GFI-1 results in the proliferation and 
accumulation of atypical myeloid progenitors that bear characteristics of both monocytes 
and granulocytes (Ref. Hock et al., 2006). 
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Dissertation goals 
 In chapter II, we demonstrate the mechanism of ZXDC mediated activation of 
MHC II genes.  We found that ZXDC and ZXDA proteins can self-associate and that the 
zinc finger region is necessary to mediate their interaction.  We also report that ZXDC 
interacted with components of the MHC II enhanceosome.  We demonstrated by co-
immunoprecipitation and Western analysis that ZXDC interacted with RFX5 and RFX-
ANK, but not, RFX-AP of the RFX heterotrimeric complex that binds to the X1 box of 
the conserved upstream sequence of MHC II gene promoter.  The ZXDA protein, 
however, was not found to interact with RFX5.  Previous findings demonstrated that 
ZXDC interacted with MHC II master regulator, CIITA (Al-kandari et al., 2000a).  Our 
model supports for a role of ZXDC-ZXDA hetero-complex to mediate protein-protein 
interactions with components of the MHC II enhanceosome resulting in an enhancement 
of the stability of the complex to activate MHC II gene transcription.  There are examples 
for enhanceosome dependent transcriptional activation in eukaryotic genes (reviewed in 
Carey, 1998; Merika and Thanos, 2001).  However, further studies are necessary to 
confirm the regulatory mechanism of ZXDC-ZXDA complex in the activation of MHC II 
gene transcription.   
 In chapter III of this dissertation, our findings strongly suggest a role for ZXD 
family proteins in myeloid development and differentiation.  We observed that ZXDC 
and ZXDA proteins interacted with the myeloid transcription factors PU.1 and GFI-1.  
We were able to broadly map ZXDC-PU.1 interaction, the N-terminal region of PU.1 
containing the activation domain interacted with the zinc finger region of ZXDC.  We 
found that ZXDC and ZXDA proteins repressed PU.1 transcriptional activity by about 
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75% and 50% respectively.  Interestingly, ZXDC was found to stabilize PU.1 protein 
expression.  Studies have demonstrated that the expression levels of PU.1 are critical for 
hematopoietic cell lineage decisions, for example, high levels of PU.1 favor monocyte 
development and low levels promote granulocyte development and differentiation (Dahl 
et al., 2003; Laslo et al., 2006).  In our studies, ZXDC and ZXDA proteins were also 
found to interact with GFI-1, a zinc finger transcriptional repressor necessary for 
neutrophil differentiation and maturation.  ZXDC was found to repress GFI-1 
transcriptional activity in a dose-dependent manner.  Chromatin immunoprecipitation 
experiments demonstrated the presence of ZXDC along with GFI-1 at the c-myc 
promoter that was earlier found to be a direct target of GFI-1 (Duan et al., 2003).  These 
findings suggest that ZXDC may have a role in affecting the recruitment and/or 
transcriptional activities of PU.1 and GFI-1 at their target gene promoters, especially, 
following differentiation of hematopoietic progenitor cells. 
 Importantly, we found that ZXDC is required for the transcription of the early 
growth response-2 (EGR-2) gene.  Earlier reports demonstrated that EGR-2 promotes 
macrophage development by activating several macrophage specific target genes, as well 
as, by repressing certain genes necessary for granulocyte development and differentiation 
(Laslo et al., 2006).  In the same report it was also demonstrated that GFI-1 and EGR-2 
function in a counter antagonistic manner.  Our findings suggest that induction of EGR-2 
by ZXDC is an important mechanism for the activation of macrophage specific genes and 
for the repression of genes required for granulocyte development.  Our goal is to confirm 
the regulatory role of ZXDC protein in monocyte development and differentiation. 
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CHAPTER II 
PROTEIN-PROTEIN INTERACTIONS OF ZXDC, 
ZXDA: ROLE IN MHC II GENE REGULATION 
 
Abstract 
 The Zinc finger, X-linked, Duplicated family members, C, A, B, C2 (ZXDC, 
ZXDA, ZXDB, ZXDC2 respectively) constitute the ZXD family of proteins.  In our 
studies, we have found several protein-protein interactions amongst the ZXD family 
members to have important role in the activation of Major histocompatibility complex 
class II (MHC II) genes.  The ZXDC and ZXDA proteins share significant nucleotide 
sequence homology and each contain ten C2H2 zinc fingers and a transcription activation 
domain (Al-Kandari et al., 2007b).  In addition, ZXDC has a C-terminal region that is 
necessary to interact with a key cofactor, Class II transactivator (CIITA) and activate 
Major histocompatability complex class II and class I (MHC II and MHC I respectively) 
genes (Al-Kandari et al., 2007a).  ZXDC and ZXDA proteins were found to self-
associate, as well as, hetero-associate and their interactions are mediated by the zinc 
fingers of both proteins.  Moreover, in vitro studies in our lab revealed that the 
association of ZXDC with ZXDA is necessary and self-association of neither protein was 
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sufficient to interact with CIITA and thereby activate MHC II gene transcription (Al-
Kandari et al., 2007b).  In addition to CIITA, we found that ZXDC interacted with two 
Regulatory factor X (RFX) proteins, namely, RFX5 and RFX-ANK (RFX having ankyrin 
repeats) which are components of the MHC II enhanceosome.  The RFX heterotrimeric 
complex consisting of RFX5, RFX-AP (RFX-associated protein), RFX-ANK binds to the 
X1 box of MHC II promoter (Burd et al., 2004).  The necessity for RFX complex in 
MHC II gene regulation is underscored by bare lymphocyte syndrome type II, a genetic 
disorder which results from mutation in one of the RFX proteins (Reith and Mach, 2001).  
Our findings support for a role of ZXDC-ZXDA heterocomplex to mediate interactions 
with components of the MHC II enhanceosome thereby enhancing the stability of the 
complex as a mechanism of activating MHC II gene transcription. 
Introduction 
Major histocompatibility complex class II (MHC II) genes express cell surface 
glycoproteins that play a central role in antigen presentation.  These proteins are 
expressed on the surface of thymic epithelial cells and professional antigen presenting 
cells namely B cells, macrophages and dendritic cells and can be induced in most other 
cell types by treatment with cytokines such as interferon γ (Drozina et al., 2005).  MHC 
II proteins present antigenic peptides to T-cell receptors (TCR) of CD4+
 
T cells 
(reviewed in Vyas et al., 2008).  Absence of MHC II expression results in a severe 
immunological disorder known as bare lymphocyte syndrome II (BLS II; Reith and 
Mach, 2001), whereas, it‟s over expression results in autoimmune diseases (Klein et al., 
1993).  Therefore, tight control of MHC II expression is critical for a normal humoral 
immune response. 
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MHC II genes are mainly regulated at the transcriptional level (Reith et al., 2001; 
Ting et al., 2002).  The promoter of MHC II genes consist of a set of conserved regions 
termed as S (or W box), X1, X2 and Y elements respectively which are necessary for 
their expression in a constitutive and inducible manner (Boss et al., 2003; Nekrep et al., 
2003).  A set of DNA binding proteins, namely, regulatory factor X complex (RFX), 
cyclic AMP response element binding protein (CREB), nuclear factor Y complex (NFY) 
bind to the X1, X2, Y boxes respectively.  Although the above proteins are ubiquitously 
distributed in most cell types, the expression of MHC II genes is determined by the key 
regulatory co-factor called class II trans activator (CIITA) (Ting et al., 2002; 
LeibundGut-Landmann et al., 2004). 
CIITA belongs to a family of proteins termed the CATERPILLER family named 
for the set of domains namely, CARD domain, transcriptional enhancer, purine binding, 
pyrin domain and lots of leucine rich repeats conserved amongst its members (Harton et 
al., 2002).  Several proteins interact with CIITA which fall in the classes of (i) DNA 
binding proteins, namely, CREB and the components of the RFX and NFY complexes, 
(ii) general transcription factors, namely, TFIID and p-Tefb, (iii) histone modifying 
proteins and (iv) proteins involved in chromatin remodeling (Moreno et al., 1999; 
Kretsovali et al., 1998; Desandro et al., 2000; Hake et al., 2000; Scholl et al., 1997; Zhu 
et al., 2000; Fontes et al., 1997; Kanazawa et al., 2000; Wright et al., 2006).   
Our lab was interested in identifying novel CIITA interacting proteins as it can 
provide a better understanding of the molecular mechanisms of CIITA mediated MHC II 
gene activation.  Yeast two-hybrid screen was performed with the leucine rich repeats (C-
terminal 807 amino acids) of CIITA as one of its major functions is to mediate protein-
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protein interactions (Kobe and Kajava, 2001) and identified a cDNA coding for a novel 
zinc finger protein named Zinc finger, X-linked, duplicated family member C (ZXDC; 
Al-Kandari et al., 2007a).  It is named based on nucleotide homology with two other 
proteins namely, ZXDA and ZXDB.  ZXDC is a 858 amino acid protein with ten 
multiple adjacent C2H2 type zinc fingers, transcription activation domain (TAD) and a C-
terminal region that interacts with the CIITA protein (Fig. 2.1, Al-Kandari et al., 2007b).  
ZXDA lacks the C-terminal CIITA binding region present in ZXDC. Figure 2.1 
illustrates a diagrammatic representation of ZXDC, ZXDA and ZXDB along with the 
regions of homology between the two proteins.  Taken together, ZXDC, ZXDA, ZXDB 
and an mRNA variant of ZXDC, ZXDC2 constitute the ZXD family. 
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Figure 2.1: Schematic representation of ZXDC, ZXDA, ZXDB representing the 
regions of percentages of homology in various domains.  The black rectangles 
represent the 10 zinc fingers of ZXDC or ZXDA, TAD: Transcriptional activation 
domain, CIITA binding is the region of ZXDC that binds to CIITA (Al-Kandari et al., 
2007b). 
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In many zinc finger proteins, the zinc fingers (ZnFs) are involved in 
macromolecular interactions.  Zinc fingers are generally involved in DNA binding, RNA 
binding and/or selective protein-protein interactions that play a significant role in the 
regulation of target genes (McCarty et al., 2003; Sun et al., 1996; Hata et al., 2000; Tsai 
et al., 1998).  In addition, there are several examples of proteins with multiple adjacent 
zinc fingers, for example, TFIIIA, WT-1, and TRA-1 where the ZnFs mediate both DNA 
and RNA biding (Cassiday et al., 2002).  Such macromolecular interactions of zinc 
fingers play a crucial role in the regulation of target genes.  These studies reveal the 
importance of complex regulatory mechanisms involved in gene activation. 
In our studies, we found several protein-protein interactions amongst the ZXD 
family members.  Co-immunoprecipitation and Western analysis demonstrated that 
ZXDC and ZXDA proteins associate with themselves as well as with each other (Al-
Kandari et al., 2007b).  Moreover, in vitro studies in our lab revealed that the association 
of ZXDC with ZXDA is necessary and self-association of neither protein was sufficient 
to interact with CIITA and thereby activate MHC II gene transcription (Al-Kandari et al., 
2007b).  We found that ZXDC and ZXDA showed a modest increase and cooperated 
with CIITA demonstrating a synergistic effect in the activation of MHC class II and 
MHC class I gene transcription. (Al-Kandari et al., 2007a).  Knockdown of ZXDC or 
ZXDA using siRNA reduced MHC II expression almost 70% by CIITA without affecting 
the expression of CIITA (Al-Kandari et al., 2007b).  Using chromatin 
immunoprecipitation, we found ZXDC at the promoter of MHC II genes in Raji cells, a B 
cell line that constitutively express MHC II, and in HeLa cells prior to and after IFNγ 
treatment (Al-Kandari et al., 2007b). 
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 In subsequent experiments, we found that ZXDC also interacts with two other 
components of the MHC II enhanceosome, namely, RFX5 (Fig. 2.5) and RFX-ANK (Fig. 
2.6).  The RFX heterotrimeric complex consisting of RFX5, RFX-AP (RFX-associated 
protein), RFX-ANK (RFX having ankyrin repeats) binds to the X1 box of MHC II 
promoter (Burd et al., 2004).  The necessity for RFX complex in MHC II gene regulation 
is underscored by a genetic disorder named bare lymphocyte syndrome type II, which 
results from mutation in one of the RFX proteins (Reith and Mach, 2001). 
 In the studies presented here we show several protein-protein interactions of the 
ZXD family members.  Co-immunoprecipitation experiments demonstrated self-
association of ZXDC and ZXDA proteins and that the zinc fingers of these proteins 
mediate their interaction.  We were also able to demonstrate that ZXDC interacts with 
RFX5 and RFX-ANK which are components of the MHC II enhanceosome complex. 
Materials and methods 
Cell culture and transfection:  Human embryonic kidney 293 (HEK293, ATCC no. 
CRL-1573) cells were maintained in Dulbecco‟s modified Eagle‟s medium (DMEM) 
supplemented with 4mM L-glutamine, 1.5g/L sodium bicarbonate, 4.5g/L glucose, 
antibiotics and 10% fetal calf serum (FBS).  Cells were maintained at 37˚C in a 
humidified air atmosphere and 5% CO2.  Cells were transfected using Lipofectamine 
2000 reagent (InVitrogen, Inc., Carlsbad, CA).  Briefly, 10
6
 cells were plated in a 6-well 
tissue culture dish 24 h prior to transfection.  For all transfections, 10µl of Lipofectamine 
2000 reagent was mixed with a total of 4 µg plasmid DNA and added to the cells 
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according to the manufacturer‟s instruction.  When necessary, empty vector was used as a 
stuffer to maintain a total of 4 µg of plasmid DNA. 
Plasmids:  The plasmids that express myc-RFX5 (pCR3-myc-RFX5), Flag-RFXANK 
(pcDNA3-Flag-RFXANK), HA-RFXAP (pEF-HA-RFXAP) were previously described 
(Nekrep et al., 2001).  The plasmid pCMV-Flag-ZXDA was created by subcloning 
ZXDA cDNA from pBluescript-ZXDA (clone ID:30347480) into pCMV-Flag vector 
using EcoR1 and BamH1 restriction sites.  The plasmid pcDNA3.1-Myc was obtained by 
annealing Myc-tag oligos and cloned into pcDNA3.1 vector using HindIII and BamH1 
restriction sites.  The plasmid pCMV-Myc-ZXDA was created by PCR amplifying 
ZXDA cDNA using pCMV-Flag-ZXDA as a template and cloned into pcDNA3-Myc 
vector using BamH1 and EcoR1 restriction sites.  To obtain pCMV-Myc-ZXDAΔN-
terminus (ZXDA construct with deletion of amino acids 1-266), the required construct 
was PCR amplified from pCMV-Flag-ZXDA and cloned into pcDNA3-Myc vector using 
BamH1 and EcoR1 restriction sites.  The plasmid pCMV-Myc-ZXDAΔZnFs (ZXDA 
construct with deletion of amino acids 267-573) was created in pcDNA3-Myc-ZXDA 
using Quikchange II XL-site directed mutagenesis kit (Stratagene) according to the 
manufacturer‟s instructions.  The plasmid pCMV-Myc-ZXDAΔC-terminus (ZXDA 
construct with deletion of amino acids 574-799) was created by PCR amplifying the 
required fragment from pCMV-Flag-ZXDA and cloned into pcDNA3-Myc vector using 
BamH1 and EcoR1 restriction sites.  The plasmid pFlag-CMV-5a-ZXDC was created by 
PCR amplifying ZXDC cDNA using pCMV-SPORT6-ZXDC as a template and cloned 
into pFlag-CMV-5a vector using HindIII and BamH1 restriction sites.  The plasmids 
pCMV-3xFlag-ZXDCΔN-terminus (ZXDC construct with deletion of amino acids 1-176) 
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and pCMV-3xFlag-ZXDCΔC-terminus (ZXDC construct with deletion of amino acids 
472-858) were generated by PCR amplifying appropriate regions of ZXDC cDNA and 
cloned into pcDNA3-3xFlag vector (an N-terminal fusion vector containing three copies 
of the Flag epitope) using BamH1 and Xba1 restriction sites. 
Co-immunoprecipitation:  HEK293 cells (10
6
) cells were transfected with the indicated 
plasmids.  Forty-eight hours after transfection, cells were lysed in 500 µl of lysis buffer 
(10mM Tris pH:8, 300mM sodium chloride, 1% Triton X-100, 0.1% sodium dodecyl 
sulphate, 25mM N-ethyl maleimide, 10mM iodoacetamide, 2mM Phenyl methyl 
sulphonyl fluoride and 1X EDTA-free protease inhibitors.  The lysate was cleared by 
centrifugation at 13,000 rpm for 15 min at 4˚C.  About 10% of the lysate was taken as 
„input control‟ to check the expression of the plasmids.  The remaining lysate was 
incubated with 4 µl of ANTI-FLAG M2 monoclonal antibody (Sigma, MO) for 3 h at 
4˚C.  The lysate-antibody mix was next incubated with 50 µl of protein A/G PLUS-
Agarose beads (Santa Cruz Biotechnology, Inc.) at 4˚C.  The beads were washed four 
times with lysis buffer, boiled with Laemmli buffer and separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (8% polyacrylamide).  The 
resolved samples were transferred to polyvinylidene difluoride (PVDF) membrane 
(Immobilon, Millipore, Inc.) using transfer buffer (25mM Tris-pH8.3, 192mM glycine, 
20% methanol).  Blots were blocked for one hour at room temperature in 1XTBST wash 
buffer (50mM Tris-pH 8, 150mM Nacl, 0.1% Tween-20) containing 5% non-fat milk and 
10% donar bovine serum.  Blots were probed with the indicated primary antibody 
followed by horse radish peroxidase (HRP)-conjugated secondary antibody (SantaCruz 
Biotechnology, Inc) in wash buffer containing 3% non-fat milk and 10% donor bovine 
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serum.  Detection was done using ECL plus (Amersham, GE Healthcare) and data were 
analyzed using Typhoon-9410 (GE Healthcare, Piscataway, NJ). 
Antibodies:  For co-immunoprecipitation and Western analysis, the following antibodies 
were used: Anti-FLAG M2 (1mg/ml, SIGMA, MO), anti-HA 12CA5 (0.4mg/ml, Roche 
Inc, IN), anti-myc 9E10 (0.4mg/ml, Roche Inc, IN), anti-GST (200µg/ml, Santa Cruz, 
CA).  The affinity purified antibody against the first twenty amino acids of ZXDC was 
generated by Bethyl laboratories Inc (Montgomery, TX; Al-Kandari et al., 2007a).  The 
HRP-conjugated anti-mouse and anti-rabbit secondary antibodies (200µg/ml) were 
obtained Santa Cruz Biotech (Santa Cruz, CA). 
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Results 
Self-association of ZXDC and ZXDA proteins: 
 The ZXDC and ZXDA proteins are zinc finger transcription factors each 
containing ten C2H2 type zinc fingers (ZnFs).  The C2H2 type zinc fingers are generally 
involved in DNA binding, RNA binding, selective protein-protein interactions or a 
combination of more than one macromolecular interaction (McCarty et al., 2003; Sun et 
al., 1996; Hata et al., 2000; Tsai et al., 1998; Wang et al., 2001; Cassiday et al., 2002).  
Although nucleic acid binding by ZnFs was the primary focus for many years, more 
recently the importance of protein-protein interactions mediated by ZnFs has come to the 
fore (reviewed in Gamsjaeger et al., 2007; Brayer et al., 2008a, 2008b).   
 We were interested to find if ZXDC and ZXDA proteins interacted, and if the 
interaction was mediated by the ten zinc fingers present in each protein.  HEK293 cells 
were transfected with plasmids that express the indicated proteins (Fig. 2.2).  Forty-eight 
hours after transfection, Co-immunoprecipitation (co-IP) and Western analysis were 
performed with the indicated antibodies.  Our results demonstrated self-association of 
ZXDC (Fig. 2.2A) and ZXDA (Fig. 2.2B) proteins.  Co-IP with a non-specific antibody 
(α-GST) served as a negative control (Fig. 2.2 A&B, lane 3).  The blots also included 
lysate controls to check the expression of the proteins. 
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        A.                                       
  
        B.                                  
Figure 2.2 ZXDC and ZXDA proteins self-associate. A. Self-association of ZXDC: 
HEK293 cells were transfected with plasmids that express HA- and FLAG-tagged 
ZXDC.  Forty-eight hours post-transfection, co-immunoprecipitation (co-IP) was 
performed with anti-FLAG (Sigma, MO) followed by Western analysis with anti-HA 
(Roche, IN).  Co-IP with a non-specific antibody (α-GST was included as a negative 
control.  B. Self-association of ZXDA HEK293 cells were co-transfected with plasmids 
that express FLAG and myc-tagged ZXDA.  Forty-eight hours post-transfection, co-IP 
and Western analysis were performed using anti-myc (Sigma, MO) and anti-FLAG 
respectively (Al-Kandari et al., 2007b). 
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The zinc fingers of ZXDA mediate interaction with ZXDC 
 We wanted to map the region of ZXDA that is necessary for interaction with 
ZXDC.  Therefore, we made deletions in the N terminus or the C terminus of the ZXDA 
protein.  A schematic representation of the deletion constructs is depicted in Fig. 2.3 (top 
panel, the black rectangles represent ten zinc fingers of the protein).  Our results 
demonstrated that deletion of the amino terminus significantly affected its interaction 
with ZXDC (Fig. 2.3, lane 3), whereas, deletion of the zinc finger region of ZXDA 
completely abolished its interaction with ZXDC (Fig. 2.3, lane 4) demonstrating that the 
zinc fingers of ZXDA mediate ZXDA-ZXDC interaction.  However, the amino terminus 
of ZXDA also contributes significantly for interacting with ZXDC. 
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Figure 2.3 Zinc-fingers of ZXDA are necessary to interact with ZXDC.  Myc-tagged 
ZXDA constructs with N-terminal, zinc finger region or C-terminal deletions were made 
(schematic representation of the ZXDA deletion constructs are shown in the top panel).  
HEK293 cells were co-transfected with plasmids that express each of the ZXDA deletion 
constructs and full-length FLAG-tagged ZXDC.  Co-IP and Western analysis were 
performed with anti-FLAG (Sigma, MO) and anti-myc (Roche, IN) respectively, 
demonstrating that the zinc finger region of ZXDA is necessary to associate with ZXDC, 
though deletion of the N-terminus reduced the interaction significantly.  Appropriate 
controls were included (Al-Kandari et al., 2007). 
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The Zinc fingers of ZXDC are necessary for interaction with ZXDA 
 In order to determine the ZXDC domain necessary for interaction with ZXDA, 
deletion of the N terminus or C terminus of ZXDC with Flag tag were made similar to as 
depicted in Fig. 2.3 (top panel).  Co-IP assays demonstrated that deletion of the N-
terminus or C-terminus of the ZXDC protein didn‟t affect its interaction with ZXDA 
(Fig. 2.4, top panel, lanes 4 and 5) suggesting that the zinc fingers of ZXDC are 
necessary to mediate interaction with ZXDA.  We were not able to demonstrate which 
Zinc fingers of ZXDC are involved as deletion of all or some of the zinc fingers resulted 
in destabilization of the protein (data not presented). 
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Figure 2.4 Zinc-fingers of ZXDC are necessary to interact with ZXDA.  FLAG 
tagged ZXDC constructs with N-terminal or C-terminal deletion were made.  HEK293 
cells were co-transfected with plasmids that express each of the deletion constructs and 
full-length myc-tagged ZXDA.  Co-IP and Western analysis were performed with anti-
FLAG (Sigma, MO) and anti-myc (Roche, IN) respectively.  Our results suggest that the 
zinc fingers of ZXDC mediate interaction with ZXDA (Al-Kandari et al., 2007b). 
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ZXDC, but not ZXDA interacts with RFX5 protein 
 Work by Wafa Al-Kandari in our laboratory established that the ZXDC-ZXDA 
complex was necessary for binding CIITA.  However, we wanted to test whether ZXDC 
interacted with other components of the MHC II enhanceosome, indicating that additional 
regulatory mechanisms for ZXDC mediated MHC II gene activation.  To find if ZXDC 
or ZXDA interact with RFX5, HEK293 cells were transfected with plasmids that express 
Flag-ZXDC or Flag-ZXDA and myc-RFX5.  Co-IP with anti-Flag and Western analysis 
with anti-myc demonstrated that RFX5 interacts with ZXDC (Fig. 2.5, lane 3), but not 
ZXDA (Fig. 2.5, lane 4).  The interaction of ZXDC-ZXDA proteins was used as a 
positive control (Fig. 2.5, lane 2), whereas, co-IP in the absence of either Flag-tagged 
proteins was used as a negative control (Fig. 2.5, lane 5).  The slower migrating band in 
Flag-ZXDC lanes represents the sumoylated ZXDC (Jambunathan and Fontes, 2007).  
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Figure 2.5 ZXDC interacts with RFX5 protein.  HEK293 cells were co-transfected 
with the indicated plasmids.  Forty-eight hours post-transfection, co-IP and Western 
analysis were performed with anti-Flag (Sigma, MO) and anti-Myc (Roche, IN) 
respectively.  This experiment demonstrated that ZXDC interacts with RFX5, which 
binds to the X-box of MHC II promoter along with RFX-AP and RFX-ANK as a 
heterotrimeric complex.  On the other hand, ZXDA did not interact with RFX5.  Co-IP of 
myc-ZXDA by Flag-ZXDC served as a positive control.  
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ZXDC also interacts with RFX-ANK protein of the RFX heterotrimeric complex 
 Since ZXDC interacted with RFX5, we wanted to know if ZXDC also associates 
with other proteins of the regulatory factor X complex, namely, RFX-ANK and RFX-AP.  
HEK293 cells were transfected with plasmids that express ZXDC and Flag-ZXDA or 
Flag-RFXANK.  Forty-eight hours post-transfection, co-immunoprecipitation was 
performed with anti-Flag and Western analysis with RFXANK protein (Fig. 2.6, top 
panel, lane 6).  Co-IP of ZXDC with Flag-ZXDA was used as a positive control (Fig. 2.6, 
top panel, lane 5).  Our results suggest that ZXDC, by interacting with components of the 
MHC II enhanceosome, may stabilize the complex as a mechanism of ZXDC-ZXDA 
mediated MHC II gene activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
 
IP: anti-Flag
IB: anti-ZXDC
IP: anti-Flag
IB: anti-Flag
Lysate control
IB: anti-ZXDC
Lysate control
IB: anti-Flag
+--+--Flag-RFX-ANK
-+--+-Flag-ZXDA
++-++-ZXDC
Heavy chain
Flag-ZXDA
Flag-RFX-ANK
 
 
Figure 2.6 ZXDC co-immunoprecipitated with RFXANK.  HEK293 cells were co-
transfected with plasmids that express ZXDC and Flag-ZXDA or Flag-RFXANK.  Forty-
eight hours post-transfection, co-IP was performed with anti-Flag and Western analysis 
with anti-ZXDC.  Co-IP of ZXDC by Flag-ZXDA was used as a positive control.  
Appropriate lysate controls were included. 
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ZXDC does not interact with RFX-AP 
 The finding that ZXDC interacted with RFX5 and RFX-ANK led us to ask if it is 
also capable of interacting with RFX-AP.  HEK293 cells were transfected with plasmids 
that express Flag-ZXDC and HA-ZXDA or HA-RFXAP.  Forty-eight hours post-
transfection, cells were lysed in lysis buffer and Co-IP was performed with anti-Flag and 
Western analysis with anti-HA.  Our results demonstrated that ZXDC does not interact 
with RFX-AP (Fig. 2.7, bottom panel, lane 5).  Co-IP of HA-ZXDA by Flag-ZXDC was 
used as a positive control (Fig. 2.7, bottom panel, lane 6).  Our results demonstrated that 
ZXDC however, does not interact with RFX-AP (Fig. 2.7, bottom panel, lane 5) of the 
RFX complex that binds to the X1 promoter element of MHC II genes.       
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Figure 2.7 ZXDC does not interact with RFXAP. HEK293 cells were co-transfected 
with plasmids that express Flag-ZXDC and HA-RFXAP or HA-ZXDA.  Forty-eight 
hours post-transfection, co-IP and Western analysis was performed with anti-Flag and 
anti-HA respectively.  This demonstrated that ZXDC does not interact with RFXAP, 
suggesting for the specificity of interaction of ZXDC with other members of the RFX 
complex, namely, RFX5 and RFXANK.  Hetero-association of ZXDC with ZXDA was 
used as a positive control. 
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Discussion 
Data presented in this chapter demonstrate selective protein-protein interactions 
between ZXD family members, ZXDC and ZXDA and between ZXDC and components 
of the MHC II enhanceosome.  We demonstrated self-association of ZXDC and ZXDA 
proteins and that the zinc fingers of both proteins mediate their interaction.  We found 
that ZXDC interacted with RFX5 and RFXANK, but not RFX-AP (Figs. 2.5, 2.6, 2.7), 
which are components of the RFX heterotrimeric complex that binds to the conserved X1 
box of the MHC II promoter (Masternak et al., 1998; Steimle et al., 1995; Villard et al., 
1997). 
The results presented here along with previous findings suggest a possible 
regulatory role for ZXDC-ZXDA complex in stabilizing MHC II enhanceosome complex 
resulting in the activation of MHC II gene transcription.  Given the important role of 
C2H2 type zinc fingers in DNA binding, we tried extensively to demonstrate direct 
binding of ZXDC to MHC II promoter region, especially the W box, but we couldn‟t 
find.  Since chromatin immunoprecipitation experiments demonstrated that ZXDC is 
present at MHC II promoters, the most likely interpretation is that ZXDC is recruited to 
MHC II promoters indirectly, via protein-protein interactions.  Our data support this 
notion.  We were able to demonstrate that ZXDC selectively interacted with components 
of MHC II enhanceosome, specifically, CIITA (Al kandari et al., 2007a), RFX5 (Fig. 
2.5), RFXANK (Fig. 2.6) and possibly some other components of the MHC II 
enhanceosome suggesting a role in stabilizing the enhanceosome complex as a 
mechanism of MHC II gene activation. 
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Studies in our lab revealed the role of a novel regulatory factor, ZXDC, in the 
activation of MHC II gene transcription.  The C-terminus of ZXDC was found to be the 
region interacting with CIITA (Al-Kandari et al., 2007a.).  Knock-down of ZXDC by 
siRNA in HEK293 cells showed significant reduction of MHC class II gene expression 
(Al-Kandari et al., 2007a).  Though ZXDA lacked the CIITA binding region, it showed a 
synergistic effect in the transcription of MHC class II genes by CIITA suggesting that it 
might cooperate with other proteins to regulate MHC II genes (Al-Kandari et al., 2007b).  
We were able to demonstrate self- (Fig. 2.2; Al-Kandari et al., 2007b) and hetero-
association (Al-Kandari et al., 2007b) of ZXDC and ZXDA proteins.  Previous findings 
demonstrated that ZXDC requires ZXDA to interact with CIITA „in vitro‟ suggesting an 
important role of hetero-association (Al-Kandari et al., 2007b).  We were able to broadly 
demonstrate that zinc fingers of ZXDA are necessary to interact with ZXDC and vice-
versa (Figs. 2.3, 2.4; Al-Kandari et al., 2007b).  We were not able to identify which zinc 
fingers of ZXDC and ZXDA mediate protein-protein interaction, as deletions of some 
zinc fingers resulted in destabilization of the protein (data not presented). 
 It was shown that re-expressing ZXDC following knock-down of endogenous 
ZXDC by RNA silencing results in partial rescue of MHC class II gene expression by 
CIITA (Al-Kandari et al., 2007a).  Transient knockdown of ZXDC or ZXDA resulted in 
significant repression of MHC II gene expression.  This decrease was not significantly 
different from knock-down of both ZXDC and ZXDA suggesting for the requirement of 
both proteins for MHC II gene regulation (Al-kandari et al., 2007b).  We observed the 
presence of ZXDC at the MHC II promoter prior to and after IFN γ treatment (Al-
Kandari et al., 2007a).  Given the important role of C2H2 type zinc fingers in 
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macromolecular interactions, they are generally involved in DNA binding, RNA binding 
or selective protein-protein interactions that play a significant role in the regulation of 
target genes (McCarty et al., 2003; Sun et al., 1996; Hata et al., 2000; Tsai et al., 1998; 
Wang et al., 2001).  Dr. Srikarthika Jambunathan in our lab identified that ZXDC 
preferentially binds to a purine rich sequence, AGGGT/A by SELEX assay.  The 
presence of this sequence at the HLA-DRA promoter suggests that it might be a potential 
binding site for ZXDC.  However, the data overall support the binding of the ZXDA-
ZXDC complex to MHC II promoters via protein-protein interactions with RFX5, 
RFXANK and CIITA. 
Although, zinc fingers were primarily known for its role in DNA binding (Wolfe 
et al., 2000), increasing evidence supports for its role in selective protein-protein 
interactions (reviewed in Gamsjaeger et al., 2007; Brayer et al., 2008a, 2008b).  Our 
study suggests for a role of zinc fingers in protein-protein interactions among ZXD 
family members (Figs. 2.3, 2.4).  Interestingly, we observed that ZXDC interacts with 
RFX5 (Fig. 2.5) and RFXANK proteins (Fig. 2.6) by co-immunoprecipitation 
experiments.  This could be a possible mechanism for the recruitment of ZXDC along 
with ZXDA at MHC II promoter.  ZXDA alone, however, did not co-immunoprecipitate 
with RFX5 (Fig. 2.5).  The RFX complex consisting of RFX5, RFX-AP, RFX-ANK 
binds to the X box as a heterotrimeric complex (Masternak et al., 1998; Steimle et al., 
1995; Villard et al., 1997; Burd et al., 2004).  ZXDC, however, did not interact with 
RFX-AP (Fig. 2.7) suggesting that these protein-protein interactions are very specific.  It 
is interesting to know if ZXDC is recruited to the promoter as a hetero-dimer along with 
ZXDA or if ZXDA is recruited later during gene activation.  From our findings, we 
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suggest that the interaction of ZXDC with several proteins that form the MHC II 
enhanceosome, for example, RFX5, RFX-ANK, CIITA stabilizes the enhanceosome 
complex resulting in the activation of MHC II gene transcription. 
In the case of MHC II enhanceosome, the individual protein-protein or protein-
DNA interactions are weak, but, multiple interactions are capable of recruiting the key 
transcriptional co-activator, CIITA (Masternak et al., 2000).  Some other examples of 
eukaryotic genes regulated by enhanceosomes include Interferon β (IFN β), T-cell 
receptor α chain and interleukin-6 (IL-6) genes (reviewed in Merika et al., 2001; Panne, 
2008).  There are several mechanisms of enhanceosome dependent transcriptional 
synergy.  Some of these include modification of chromatin structure for the recruitment 
of preinitiation complex, enabling nucleosome modification and enhancing the stability 
of enhanceosome (reviewed in Merika et al., 2001; Carey, 1998; Panne, 2008). 
 At present, we do not know the exact mechanism how ZXDC-ZXDA complex 
activates MHC II gene transcription.  It is possible that ZXDC-ZXDA complex through 
its interaction with CIITA, RFX5, RFXANK and possibly other components (CREB, 
NFY or chromatin remodeling factors) might stabilize the enhanceosome complex 
resulting in gene activation.  This suggests as a potential mechanism for ZXDC-ZXDA 
recruitment at the class II promoter and resulting in the activation of MHC II genes. 
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CHAPTER III 
THE INTERACTION OF ZXDC PROTEIN WITH THE 
HEMATOPOIETIC TRANSCRIPTION FACTORS, PU.1 
AND GFI-1: A ROLE IN MYELOPOIESIS 
 
Abstract 
 The ZXD family of proteins seems to have a broader role in gene regulation, 
beyond MHC II gene transcription.  We have found that ZXDC interacts and represses 
the transcriptional activities of two myeloid transcription factors, namely, purine box 
binding protein, PU.1 and growth factor independent-1 (GFI-1).  Our studies also 
demonstrated that the binding of ZXDC protein to PU.1, stabilizes the PU.1 protein.  The 
MYC gene promoter, a known target of GFI-1, was found to be bound by the ZXDC 
protein.  These results demonstrate that ZXDC affects PU.1 and GFI-1 transcriptional 
activities and/or recruitment at their target gene promoters.  Preliminary results by our lab 
suggest that ZXDC favors monocyte development.  Specifically, ZXDC activates the 
transcription of the Egr-2 (Early growth response-2) gene.  The expression of Egr-2 is 
associated with monocyte specific gene expression and repression of granulocyte genes 
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thus favoring monopoiesis (Laslo et al., 2006; Krishnaraju et al., 2001).  Previous studies 
by others have demonstrated that GFI-1 and Egr-2 function in an antagonistic manner 
(Laslo et al., 2006).  We propose a model where ZXDC, by affecting PU.1 and GFI-1 
recruitment and transcriptional activities at their target gene promoters, and by activating 
Egr-2 activity and expression, has an important regulatory role in monopoiesis.   
Introduction 
A large network of several ubiquitous and tissue specific transcription factors play 
an important role in the differentiation and development of hematopoietic cells (reviewed 
in Rosenbauer et al., 2007; Friedman, 2007).  Mutation of the genes encoding several of 
these proteins or misregulation of their expression was found to contribute to leukemia 
(Rosenbauer et al., 2004, 2006, 2007; Huang et al., 2008; Orkin, 2000; Tenen, 2003, 
Table 1.2).  The transcription factor PU.1/Spi-1 is considered the master regulator for 
several myeloid specific genes.  PU.1 was first identified as the genomic locus rearranged 
by the spleen focus forming virus proviral insertion (Spi-1) in many erythroid leukemias 
(Moreau-Gachelin et al., 1988). 
The expression of PU.1 is restricted to hematopoietic cells (except mature T 
cells), especially, in all myeloid lineages, B-cell lineages, developing T cells, a subtype of 
Th2 cells and hematopoietic stem cells (Kastner and Chan, 2008).  PU.1 is a 
transcriptional activator that belongs to the Ets family and contains an N-terminal 
activation domain and C-terminal basic helix-turn-helix motif necessary for DNA binding 
and binds to the purine-rich sequence (5‟ GAGGAA 3‟) to regulate target gene 
expression (reviewed in Friedman, 2007).   
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 The interaction of PU.1 with several transcription factors such as GATA-1, 
CCAAT/enhancer binding protein α (C/EBP α), growth factor independent-1 (GFI-1), B 
cell-specific activator protein and Ski is critical for determining hematopoietic cell fates 
by regulating the expression of lineage specific genes (Nerlov et al., 2000; Zhang et al., 
1999; Reddy et al., 2002; Maitra and Atchison, 2000; Dahl et al., 2007; Ueki et al., 2008).  
Interestingly, all the above factors inhibit the ability of PU.1 to transactivate its target 
genes at different stages of differentiation and development.  The expression level of 
PU.1 was found to be very important for lineage decisions.  In myeloiod progenitor cells, 
high levels of PU.1 have been reported to favor monopoiesis, whereas, low levels favor 
granulopoiesis (Dahl et al., 2003; Laslo et al., 2006).  Growth factor independent 1 (GFI-
1) was first identified as the gene activated by the insertion of Moloney murine leukemia 
virus in rat T cell lymphoma cell line that acquired interleukin-2 growth independence 
(Gilks et al., 1993).  GFI-1 is expressed mainly in common lymphoid progenitors, 
developing B- and T-lymphocytes, granulocyte-monocyte progenitor, granulocytes, 
hematopoietic stem cells (Zeng et al., 2004; Yucel et al., 2004).  GFI-1 also has critical 
role in hematopoietic stem cell maintenance (reviewed in Duan and Horwitz, 2005).  
GFI-1 is a transcriptional repressor containing an N-terminal repression domain called 
the SNAG (Snail/Gfi1) domain and six C-terminal zinc fingers required for DNA binding 
(Grimes et al., 1996; Zweidler-Mckay et al., 1996).  The sequence 
TAAATCAC(A/T)GCA (the core sequence is underlined) was identified as the GFI-1 
binding site (Zweidler-Mckay et al., 1996).   
 GFI-1 opposes gene activation by PU.1, an activity found to be necessary for 
myeloid progenitors to differentiate into granulocytes (Dahl et al., 2007).  GFI-1 knock-
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out mice and mutations in GFI-1 in humans that inhibit the ability of GFI-1 to repress 
PU.1 were found to result in neutropenia (Hock et al, 2003; Person et al., 2003).  In this 
condition, the myeloid progenitors show a block in differentiation and exhibit 
characteristics of both granulocytes and monocytes.  Previous studies demonstrated that 
GFI-1 and Egr-2/Nab2 function in a counter antagonistic manner to drive myeloid 
progenitors into neutrophils or macrophages (Laslo et al., 2006).  Such antagonistic 
interplay between several lineage determinants was found to be critical for resolving 
mixed lineage states (Orkin et al., 2000).  Figure 3.1 outlines the role of PU.1 and GFI-1 
along with other critical transcription factors necessary for determining granulocyte or 
monocyte cell lineage decisions and development.      
 In the studies presented here, we show that ZXDC interacted with PU.1 and GFI-
1 and the zinc fingers of ZXDC mediate these protein-protein interactions.  ZXDC 
repressed the ability of GFI-1 to activate transcription in a dose-dependent manner and 
activated the Egr-2 promoter.  The Myc promoter, a known target of GFI-1 was also 
found to be a direct target of ZXDC as demonstrated by chromatin immunoprecipitation 
experiments in HEK293 cells.   
We also found that ZXDC has a role in PU.1 protein stabilization.  Earlier studies 
by others demonstrated that the expression levels of PU.1 are critical for determining 
hematopoietic cell lineage decisions and its deregulated expression can result in 
leukemias and lymphomas (DeKoter et al., 2000, 2007; Anderson et al., 2002; Dahl et al., 
2003; Cook et al., 2004; Rosenbauer et al., 2004, 2006; Huang et al., 2008; Kastner et al., 
2008).  Therefore, it is important to study the molecular mechanism of ZXDC mediated 
PU.1 protein stabilization.  Preliminary results in HL-60 cells by the over-expression or  
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Figure 3.1 A model for PU.1 and GFI-1 mediated transcriptional regulation of 
granulocyte and monocyte lineage commitment and maturation:  The figure outlines 
the role of important transcription factors involved in monocyte and granulocyte 
differentiation and development.  Hematopoietic stem cell (HSC) differentiates into 
lymphoid-myeloid progenitor (LMP) directed by PU.1 or into megakaryocyte erythroid 
progenitor (MEP) directed by GATA-binding protein 1 (GATA-1).  Cross-inhibition 
between PU.1 and GATA-1 determines lymphoid-myeloid or erythroid lineages.  Similar 
cross-inhibition occurs between C/EBPα and lymphoid factors Pax5 and Notch to direct 
lymphoid or granulocyte-monocyte lineages.  MEPs give rise to erythrocytes (RBC) or 
megakaryocytes (mega).  High levels of PU.1 direct granulocyte-monocyte progenitor 
(GMP) to monocytic lineage.  C/EBPα induction of PU.1 enhances PU.1 activity.  AP-1 
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and NF-κB may also have positive roles in this pathway.  For GMP to differentiate into 
granulocyte lineage requires C/EBPα and reduced PU.1 levels.  Vitamin D receptor 
(VDR), interferon regulatory factor-8 (IRF-8), mafB, early growth response proteins-1,2 
(Egr-1, Egr-2) direct monocytic maturation, whereas, retinoic acid receptors (RARs) and 
C/EBPє direct granulocytic differentiation. Loss of CDP- and HoxA10-repressive 
activities; and GFI-1 mediated repression is necessary for granulocyte differentiation. 
Cross-inhibition between GFI-1 and Egr-1,2 maintains GMP decisions.  This schematic 
diagram (Fig. 3.1) was adapted from a review article written by Friedman, 2007. 
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silencing of ZXDC followed by induction with monocytic differentiation agent (PMA) 
demonstrated that ZXDC favors monocyte development.  Taken together, our findings 
suggest that ZXDC has a regulatory role by stabilizing PU.1 protein expression and/or by 
affecting GFI-1 and PU.1 transcriptional activities and their recruitment at their target 
gene promoters following differentiation of hematopoietic progenitor cells.  In addition, 
activation of the Egr-2 promoter activity and expression by ZXDC, supports the notion 
that ZXDC favors monopoiesis.  The results presented in this chapter strongly suggest an 
important role for ZXDC in monocyte development and differentiation.   
Materials and methods 
Cell culture and Transfections:  Human embryonic kidney 293 (HEK293; ATCC No. 
CRL-1573) cells and HeLa cells were maintained in Dulbecco‟s modified Eagle‟s media 
(DMEM) supplemented with 4mM L-glutamine, 1.5g/L sodium bicarbonate, 4.5g/L 
glucose, antibiotics and 10% fetal bovine serum (FBS).  Cells were maintained at 37˚C in 
a humidified air atmosphere and 5% CO2.  HEK293 cells were transfected using 
Lipofectamine 2000 reagent (InVitrogen, Inc., Carlsbad, CA).  Briefly, 2x10
5
 cells were 
plated in a 24-well plate 24 h prior to transfection.  For all transfections, 2 µl of 
Lipofectamine 2000 was mixed with a total of 800 ng plasmid DNA and added to the 
cells according to the manufacturer‟s instructions.  HeLa cells were plated at 105 cells in 
a 6-well tissue culture dish 24 h prior to transfection.  These cells were transfected with 
TransPass HeLa transfection reagent (New England Biolabs, MA).  For all transfections, 
3 µg plasmid DNA was mixed with 3 µl TransPass HeLa transfection reagent.  When 
necessary, empty vector was used as a stuffer to keep a total of 3µg plasmid DNA.   
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Luciferase assay:  For luciferase reporter experiments, all transfections included plasmid 
for Renilla luciferase reporter driven by the herpes simplex virus-thymidine kinase 
promoter (phRL-TK-Renilla) to serve as an internal control.  Forty-eight hours after 
transfection, luciferase assay was performed using the Dual luciferase kit (Promega, Inc., 
Madison, WI) according to the manufacturer‟s instructions.  All firefly luciferase values 
were normalized to the amounts of Renilla luciferase expression and relative fold 
increase were calculated.  Mean values of three independent transfections are shown and 
error bars represent the standard error of the mean. 
Plasmids:  The plasmid pCMV5a-Flag-ZXDC was created by PCR amplifying ZXDC 
cDNA (GenBank accession No. AL553476) and cloned using HindIII and BamH1 
restriction sites of pCMV5a-Flag vector (Sigma, MO).  The plasmids, pCMV-3xFlag-
ZXDC, pCMV-3xFlag-ZXDCΔN-terminus (ZXDC construct with deletion of amino 
acids 1-176) and pCMV-3xFlag-ZXDCΔC-terminus (ZXDC construct with deletion of 
amino acids 472-858) was created by PCR amplifying appropriate regions of ZXDC 
cDNA and cloned into pcDNA3-3xFlag vector (an N-terminal fusion vector containing 
three copies of the Flag epitope) using BamH1 and Xba1 restriction sites.  The plasmid 
pCMV-Flag-ZXDA was created by subcloning ZXDA cDNA from pBluescript-ZXDA 
(clone ID:30347480) into pCMV-Flag vector using EcoR1 and BamH1 restriction sites.  
The full-length human PU.1 cDNA (isolated from THP-1 cell line; pcDNA3.1-ZEO-
hPU.1) and myc-tagged PU.1 plasmids with deletions of the activation domain 
(pCMV/myc/cyto-PU.1∆A) or the DNA binding Ets domain (pCMV/myc/cyto-PU.1∆E) 
were gifts from Dr. Christophe Nicot (Reference: Datta et al., 2006).  The plasmid 
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pcDNA3.1-myc-PU.1 was obtained by PCR amplifying hPU.1 cDNA using the following 
primers and cloned into pcDNA3.1-myc vector using EcoR1 and Xho1 restriction sites.  
Forward primer: 5‟ GATGAATTCCCTTACAGGCGTGCAAAATGG 3‟  
Reverse primer: 5‟ GATCTCGAGTCAGTGGGGCGGGTGGCGCCG 3‟   
The PU.1 reporter plasmid (pTK-3xPU.1-luciferase) containing three PU.1 binding sites 
upstream of minimal thymidine kinase promoter driving the luciferase gene was also a 
gift from Dr. Christophe Nicot.  The expression plasmid for rat Growth factor 
independent-1 (GFI-1) was a gift from Dr. Marshall Horwitz.  The Gfi reporter plasmid 
(pT81-4xGfi-luciferase) was created by annealing the following oligos containing 4xGfi 
binding sites (CACACCAAATCACTGC) and cloned upstream of minimal thymidine 
kinase promoter containing pT81 luciferase reporter plasmid (Addgene plasmid 11783) 
using BamH1 and HindIII restriction sites at 5‟ and 3‟ ends respectively. 
Gfi oligo 1: 5‟GATCCCACACCAAATCACTGCCACACCAAATCACTGCCACACC 
AAATCACTGCCACACCAAATCACTGCA 3‟;  
Gfi oligo 2: 5‟ AGCTTGCAGTGATTTGGTGTGGCAGTGATTTGGTGTGGCAGTG 
ATTTGGTGTGGCAGTGATTTGGTGTGG 3‟. 
The plasmid pRL∆CMV was used as an internal control for Egr-2 luciferase assays.  This 
plasmid was generated by the removal of the CMV promoter in pRL-CMV vector 
(Promega) using restriction enzymes BglII and Pst I followed by blunting of the ends 
with DNA polymerase I (Klenow).  The blunt ends were ligated using T4 DNA ligase.  
The expression plasmid for Renilla luciferase (phRG-TK-Renilla) was purchased 
(Promega, Madison, WI).  The plasmid pEgr2-luciferase reporter is generated by cloning 
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a 922 base pair amplification product containing Egr2 promoter into pGL3basic using 
NheI and HindIII restriction sites.  The following primers were used for PCR 
amplification: 
Pegr2-1: 5‟ AAGCTAGCATTTCTCTCGAAGCTCCC 3‟ 
Pegr2-2: 5‟ GGAAGCTTTGTCTATTTGCCACTGAC 3‟ 
Antibodies:  For co-immunoprecipitation and Western analysis, the following antibodies 
were used:  Anti-FLAG M2 (1mg/ml, SIGMA, MO), anti-HA 12CA5 (0.4mg/ml, Roche 
Inc, IN), anti-myc 9E10 (0.4mg/ml, Roche Inc, IN), anti-GST (200µg/ml, Santa Cruz, 
CA), anti-beta actin (Santa Cruz, CA).  The HRP-conjugated anti-mouse and anti-rabbit 
secondary antibodies (200µg/ml) were obtained Santa Cruz Biotech (Santa Cruz, CA). 
Co-immunoprecipitation and Western analysis:  HEK293 cells (10
6
) cells were 
transfected with the indicated plasmids.  Forty-eight hours after transfection, cells were 
lysed in 500 µl of lysis buffer (10mM Tris pH:8, 300mM sodium chloride, 1% Triton X-
100, 0.1% sodium dodecyl sulphate, 25mM N-ethyl maleimide, 10mM iodoacetamide, 
2mM Phenyl methyl sulphonyl fluoride and 1X EDTA-free protease inhibitors.  A 
phosphatase inhibitor, Sodium fluoride at 50 mM concentration was included in the lysis 
buffer to stabilize phosphorylated PU.1 when needed.  Following sonication, the lysate 
was cleared by centrifugation at 13,000 rpm for 15 min at 4˚C.  About 10% of the lysate 
was taken as „input control‟ to check the expression of the plasmids.  The remaining 
lysate was incubated with 4 µl of ANTI-FLAG M2 monoclonal antibody (Sigma, MO) 
for 3 h at 4˚C.  The lysate-antibody mix was next incubated with 50 µl of protein A/G 
PLUS-Agarose beads (Santa Cruz Biotechnology, Inc.) at 4˚C.  The beads were washed 
four times with lysis buffer, boiled with Laemmli buffer (100mM Tris-pH 6.8, 2%  
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β-mercaptoethanol, 4% SDS, 20% glycerol and 0.02% w/v bromophenol blue) and 
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; 
8% polyacrylamide).  The resolved samples were transferred to polyvinylidene difluoride 
(PVDF) membrane (Immobilon, Millipore, Inc.) using transfer buffer (25mM Tris-pH8.3, 
192mM glycine, 20% methanol).  Blots were blocked for one hour at room temperature 
in 1XTBST wash buffer (50mM Tris-pH 8, 150mM Nacl, 0.1% Tween-20) containing 
5% non-fat milk and 10% donor bovine serum.  Blots were probed with the indicated 
primary antibody followed by horse radish peroxidase (HRP)-conjugated secondary 
antibody (SantaCruz Biotechnology, Inc) in wash buffer containing 3% non-fat milk and 
10% donor bovine serum.  Detection was done using ECL plus (Amersham, GE 
Healthcare) and data were analyzed using Typhoon-9410 (GE Healthcare, Piscataway, 
NJ). 
Cycloheximide treatment: To check if ZXDC has a role in PU.1 protein stabilization, 
HEK293 cells were transfected with plasmids that express myc-PU.1 or along with Flag-
ZXDC.  Twenty-four hours after transfection, cells were either untreated or treated with 
100μg/ml Cycloheximide (Sigma) to inhibit protein synthesis.  Cells were harvested at 
different time points (1h, 2h, 4h, 8h, 24h) following cycloheximide treatment.  Cells were 
lysed in lysis buffer (10mM Tris pH:8, 300mM sodium chloride, 1% Triton X-100, 0.1% 
sodium dodecyl sulphate, 25mM N-ethyl maleimide, 10mM iodoacetamide, 2mM Phenyl 
methyl sulphonyl fluoride and 1X EDTA-free protease inhibitors, 50mM sodium 
fluoride), protein concentration of the cell lysates was determined using Bio-rad protein 
quantification assay and 50μg of total protein was analyzed by Western analysis.     
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Chromatin immunoprecipitation assay:  HEK293 cells (6x10
6
) were plated in a 10 cm 
tissue culture dish 24 hours prior to transfection.  The cells were transfected with 6 μg 
each of ZXDC and GFI-1 expression plasmids (pCMV5a-Flag-ZXDC and pCS2-myc-
GFI-1).  Forty-eight hours post-transfection, cells were fixed in 1% formaldehyde 
(SIGMA, MO) for 10 minutes at room temperature.  The cross-linking was quenched by 
the addition of glycine (SIGMA, MO) at a concentration of 0.125M for five minutes at 
room temperature.  The cells were washed with ice-cold PBS and scraped from tissue 
culture plate and transferred to a microcentrifuge tube and collected by centrifuging at 
700xg for 4 minutes at 4˚C.  The cell pellet was resuspended in 500 µl of SDS-lysis 
buffer (50mM Tris, pH 8.1, 1% SDS, 10mM EDTA).  2 μl of RNaseA (0.5 mg/ml stock) 
was added to the cell lysate and resuspended on ice for 10 minutes.  The cell lysate was 
sonicated on ice to generate soluble chromatin with DNA fragments of lengths less than 
3kb.  The sheared chromatin was cleared by centrifuging at 13000xg, 4˚C, for 15 
minutes.  The cleared chromatin was transferred to a 15ml tube and diluted (1:10) with 
dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl-pH 
8.1, 167mM NaCl).  The diluted chromatin was pre-cleared with rabbit IgG for one hour 
at 4˚C, followed by incubation with 60μl protein G agarose beads (Upstate Inc., 
Temecula, CA) for another hour.  The beads were collected by centrifuging at 1000xg for 
3 minutes at 4˚C.  The pre-cleared chromatin was transferred to a fresh tube and 1% of it 
was set aside as input control.  The remaining fraction was aliquoted into separate 
microcentrifuge tubes and incubated overnight with 5 μg of anti-Flag (Affinity 
Bioreagents, CO), anti-myc (Roche Inc., IN), anti-RNA polymerase II (abcam In., MA) 
or non-specific IgG (abcam In., MA).  Following incubation with antibody, the sheared 
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chromatin was incubated with 40 μl of Protein G Dynabeads (Invitrogen Inc., CA) for an 
additional hour at 4˚C.  The beads were separated using a magnetic separator and washed 
with the following buffers by mixing (with inversion) the beads in each buffer for 5 
minutes at 4˚C- Low-salt immune complex wash buffer (0.1% SDS, 1% Triton X-100, 
2mM EDTA, 20mM Tris-HCl, pH 8.1, 150mM NaCl), High-salt immune complex wash 
buffer (0.1% SDS, 1% TritonX-100, 2mM EDTA, 20mM Tris-HCl, pH 8.1, 500mM 
NaCl), LiCl immune complex wash buffer (0.25 M LiCl, 1% NP-40, 1% sodium 
deoxycholic acid, 1mM EDTA, 10mM Tris, pH 8.1) and washed twice with TE buffer 
(10mM Tris-HCl, pH 8, 1mM EDTA).  The chromatin complex was eluted with 400 μl of 
elution buffer (1% SDS, 0.1M NaHCO3).  The DNA-protein crosslinking was reversed 
by adding 16 μl of 5M NaCl to 400 μl of the eluate followed by incubation at 65˚C for 
four hours.  The protein was degraded by the addition of 6 μl of Proteinase K (10 mg/ml 
stock) (Invitrogen Inc., CA) and incubated at 45˚C overnight.  The DNA was purified 
using the PCR purification kit (Qiagen, CA) according to the manufacturer‟s protocol.  
The following primers for Myc and beta-actin (negative control, Nakazawa et al., 2007) 
were used with 2μl DNA and 2X Power SYBR green PCR Mastermix (Applied 
Biosystems, CO) for real-time PCR analysis using IQ5 real-time PCR detection system 
(BioRad Inc., CA).    
Myc forward primer: 5‟GAAGGTATCCAATCCAGATAGCTGTGC 3‟ 
Myc reverse primer: 5‟ GAGCGTGGGATGTTAGTGTAGATAGGG 3‟ 
beta-actin forward primer: 5‟ CATCACCATTGGCAATGAGC 3‟ 
beta-actin reverse primer: 5‟ CATACTCCTGCTTGCTGATC 3‟ 
RNA preparation and Semiquantitative RT-PCR analysis:  Total RNA was isolated 
with TRIzol reagent (InVitrogen, Inc.) as described previously (Chomczynski et al., 
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1993).  cDNA was synthesized with QuantiTect Reverse transcription kit (Qiagen) from 
1μg of total RNA.  The relative expression levels of Egr-2, Egr-4, ZXDC or beta-2-
microglobulin (control) were determined by PCR amplification using Platinum PCR 
SuperMix (Invitrogen Inc., CA) and the following gene specific primers.  The PCR 
products were resolved by 8% poly acrylamide gel electrophoresis with ethidium 
bromide staining and data were analyzed using Typhoon scanner (GE Healthcare, 
Piscataway, NJ). 
Egr-2 forward primer: 5‟ GTAAGCCCTTTCCCTGCCCACTG 3‟ 
Egr-2 reverse primer: 5‟ GGTCCCTCGCTGCCTCCACTG 3‟ 
Egr-4 forward primer: 5‟ TGCTCCACCTTAGCGAGTTT  3‟ 
Egr-4 reverse primer: 5‟ CAAAGCCCAGCTCAAGAAGT 3‟ 
ZXDC forward primer: 5‟ CAGCAAGAACTGATTACCGAGC 3‟ 
ZXDC reverse primer: 5‟ GCATGGAAATGGGGAGGACTCA 3‟ 
β2 microglobulin forward primer: 5‟ GTGCTCGCGCTACTCTCTCT 3‟ 
β2 microglobulin reverse primer: 5‟ TCTCTGCTGGATGACGTGAG 3‟ 
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Results 
ZXDC and ZXDA proteins interact with the myeloid transcription factor, PU.1 
 It was previously reported that ZXDC was cloned in a yeast two hybrid assay with 
the GFI-1 protein (Duan et al., 2007).  During experiments to confirm this finding, we also 
found that ZXDC could interact with the hematopoietic transcription factor PU.1, by co-
immunoprecipitation assay (Fig. 3.2).  HEK293 cells do not express PU.1 and were co-
transfected with expression plasmids for myc-PU.1 and Flag-ZXDC or Flag-ZXDA.  Co-
immunoprecipitation (co-IP) with anti-Flag and Western blot with anti-myc demonstrated 
that both ZXDC and ZXDA proteins interacted with PU.1 in vivo.  As a negative control 
for co-IP, HEK293 cells were transfected with only the myc-PU.1 expression plasmid 
(Fig. 3.2, lane 3).  A non-specific band was detected in the absence of either Flag-tagged 
protein (Fig. 3.2; panel 2, lane 3).  The slower migrating band in myc-PU.1 lanes 
represent the phosphorylated PU.1 (reviewed in Sylvia and Fenton, 2000), whereas, the 
slower migrating band in the ZXDC lane represents the sumoylated form of the ZXDC 
protein (Jambunathan and Fontes, 2007). 
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FIGURE 3.2 ZXDC/ZXDA co-immunoprecipitate with PU.1:  HEK293 cells were co-
transfected with pcDNA3.1-myc-PU.1 and pFlag-CMV-5a-ZXDC or pCMV-Flag-
ZXDA.  Forty-eight hours after transfection, the cell lysate was subjected to co-IP with 
anti-Flag followed by Western analysis with anti-Myc.  The figure includes appropriate 
controls.  The slower migrating band in Myc-PU.1 lanes represent the phosphorylated 
form of PU.1, where as, the slower migrating band in Flag-ZXDC lane (IP&IB with anti-
Flag) represents the sumoylated form of ZXDC. 
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The zinc fingers of ZXDC mediate interaction with PU.1 
To map the region of ZXDC necessary for interaction with PU.1 protein, an N-
terminal (ZXDC construct with deletion of amino acids 1-176) or C-terminal deletion 
(ZXDC construct with deletion of amino acids 472-858) was made in the ZXDC protein 
(Fig.3.3, top panel).  Deletion of the N-terminus or the C-terminus did not affect 
interaction with PU.1 (Fig. 3.3) suggesting that the zinc finger region of the ZXDC 
protein mediates its interaction with PU.1.  We were not able to finely map which zinc 
fingers are involved as deletion of all or some zinc fingers of ZXDC resulted in 
destabilization of the protein (data not presented).       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.3 Zinc fingers of ZXDC mediate interaction with PU.1. Schematic 
representation of ZXDC deletion constructs with deletion of the N-terminus or the C-
terminus of ZXDC is shown in the top panel.  HEK293 cells were transfected with 
plasmids that express 3X Flag-ZXDC deletion constructs with deletion of the N-terminus 
or C-terminus and myc-PU.1.  Co-IP was performed with anti-Flag and Western analysis 
was performed with anti-Myc.  Our results demonstrate that deletion of N-terminus or C-
terminus of ZXDC did not affect its interaction with PU.1 (Fig. 3.3, lanes 1 & 2, top 
panel) suggesting that the zinc fingers of ZXDC are necessary to mediate ZXDC-PU.1 
interaction.  We were not able to demonstrate which zinc fngers are necessary as deletion 
of some or all zinc fingers resulted in destabilization of the protein (data not presented). 
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The region of PU.1 containing the activation domain is necessary for interaction 
with ZXDC 
 Several key regulatory proteins interact with distinct domains of the PU.1 protein.  
For example, the amino terminal transcription activation domain of PU.1 interacts with 
TFIID, TBP, GATA1, GATA2, glucocorticoid receptor and heat shock protein, HSP90 
whereas, the PEST domain of PU.1 interacts with Interferon regulatory factor family of 
proteins (Reddy et al., 2002; Dahl et al. 2007; Huang et al., 2007; Rekhtman et al., 1999; 
Vangala et al., 2003; Bassuk and Leiden, 1995; Aittomaki et al., 2004; Gauthier et al., 
1993; Wara-aswapati et al., 1999).  The PU.1 DNA binding, Ets domain interacts with c-
Jun, GATA1, GATA2, CCAAT enhancer binding protein α (C/EBPα) and CCAAT 
enhancer binding protein β (C/EBPβ), acute myeloid leukemia 1 (reviewed in Tenen, 
2003).  This knowledge can help us understand the regulatory mechanisms of such 
protein-protein interactions.  For example, the C-terminal zinc finger of GATA1 protein 
competes with the basic region of c-Jun for interaction with the Ets domain of PU.1 
(Zhang et al., 1999, Liew et al., 2006) and this is a potential mechanism to prevent 
myeloid gene activation in erythroid cells. In another example, the leucine zipper of 
C/EBPα competes with c-Jun for interaction with PU.1 in the absence of DNA (Reddy et 
al., 2002), whereas, in the presence of DNA, it cooperates and enhances PU.1 activity to 
activate myeloid promoters (Oelgeschlager et al., 1996).  We wanted to identify the PU.1 
domain that is necessary for interaction with ZXDC as it can give an idea about the 
functional consequences of PU.1-ZXDC interaction.  To determine the PU.1 domain 
necessary for interaction with ZXDC, expression plasmids for myc-PU.1∆A (deletion of 
the activation domain of PU.1) or myc-PU.1∆E (deletion of the Ets domain of PU.1; Fig. 
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3.4A) and Flag-ZXDC were transfected into HEK293 cells.  Co-immunoprecipitation 
with anti-Flag and Western analysis with anti-myc demonstrated that deletion of the 
region containing the activation domain of the PU.1 protein inhibits its interaction with 
ZXDC (Fig. 3.4B). 
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B. 
FIGURE 3.4 A. Schematic representation of the full-length human PU.1 and its 
deletion constructs. PU.1 ∆E lacks the DNA binding Ets domain and PU.1∆A lacks the 
activation domain of PU.1.  The black rectangle represents the Myc epitope at the C-
terminus.  B. ZXDC interacts with the region of PU.1 containing the activation 
domain: HEK293 cells were co-transfected with PU.1∆E-myc (myc-tagged PU.1 with 
deletion of the Ets domain) or PU.1∆A-myc (myc-tagged PU.1 with deletion of the 
Activation domain) alone or along with pFlag-CMV-5a-ZXDC.  Forty-eight hours post-
transfection, co-IP was performed with anti-Flag and Western analysis with anti-Myc.  
All samples included 10% of the lysate taken prior to co-IP as input control. 
1 156 264Activation domain Ets domain
PU.1 ∆E
PU.1 ∆A
PU.1 (full-length)
IB: Anti-Flag
IB: Anti-Myc
+-+--+-+--Flag-ZXDC
++---++---Myc-PU.1∆E
--++---++-Myc-PU.1∆A
IP: Anti-Flaglysate control
Non-specific
Heavy chain
86 
ZXDC and ZXDA proteins repressed PU.1 transcriptional activity 
 PU.1 is a myeloid master regulator that is necessary for transactivation of several 
myeloid specific genes (Krysinska et al., 2007, Scott et al., 1994).  The interaction of 
ZXDC and ZXDA proteins with PU.1 was found to have a functional role as they 
repressed activation of a PU.1-responsive reporter plasmid by about 75% and 50% 
respectively (Fig. 3.5).    Luciferase reporter assay in HeLa cells transfectd with plasmids 
expressing the indicated proteins and a luciferase reporter containing three PU.1 binding 
sites upstream of a minimal thymidine kinase promoter demonstrated that ZXDC and 
ZXDA proteins have a repressive effect on PU.1 transcriptional activation.  We were not 
surprised by ZXDA functioning similar to ZXDC, that is having a similar repressive 
effect on PU.1 activity, since ZXDC and ZXDA proteins share significant amino acid 
sequence homology especially in the zinc finger region (Alkandari et al., 2007b).  It is 
possible that ZXDC represses PU.1 activity by preventing its DNA binding, but, this 
mechanism is less likely as ZXDC does not interact with PU.1 Ets domain and therefore 
may not compete with this region of PU.1 for DNA binding. The bottom panel is a 
Western control to confirm that the co-expression of ZXDC or ZXDA does not reduce 
PU.1 expression.  Interestingly, we observed enhanced PU.1 protein levels specifically 
when ZXDC (Fig. 3.5, lane 5) but not ZXDA (Fig. 3.5, lane 6) was over-expressed along 
with PU.1. 
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FIGURE 3.5: ZXDC and ZXDA repressed PU.1 transcriptional activity. HeLa cells 
were plated at 105 cells in 6-well plate.  After 24 hours, cells were co-transfected with 
pcDNA3.1-myc-PU.1, pFlag-CMV-5a-ZXDC, pCMV-Flag-ZXDA plasmids as indicated 
and the PU.1 reporter plasmid, pTK-PU.1-3X-luciferase containing three PU.1 binding 
sites upstream of minimal thymidine kinase promoter driving the luciferase gene.  Forty-
eight hours after transfection, Luciferase assay was performed.  ZXDC and ZXDA were 
found to repress the transcriptional activity of PU.1 by 75% and 50% respectively.  The 
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bottom panel in Fig. 3.5 is a Western control to check for the expression of proteins for 
the above luciferase assay. 
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ZXDC has a role in PU.1 protein stabilization 
 The expression level of PU.1 was found to have an important role in determining 
hematopoietic cell fate and lineage decisions (Moreau-Gachelin et al., 1988; DeKoter et 
al., 2000; Anderson et al., 2002; Dahl et al., 2003; Cook et al., 2004; Rosenbauer et al., 
2004, 2006; Huang et al., 2008).  In order to determine if ZXDC stabilizes PU.1 protein 
expression, HEK293 cells were co-transfected with expression plasmids for myc-PU.1 by 
itself or with Flag-ZXDC.  Twenty-four hours later, the cells were treated with 
cycloheximide, and harvest at time intervals to determine if over-expression of ZXDC 
affected PU.1 protein stability.  Our results demonstrated significant decrease in PU.1 
protein expression levels by 8h in cells expressing PU.1 alone (Fig. 3.6, lane 5).  On the 
other hand, over-expression of ZXDC stabilized PU.1 expression, the levels remaining 
high even after 24h of cycloheximide treatment.  At present, we do not know the 
mechanism of ZXDC mediated PU.1 protein stabilization and further studies are needed.  
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FIGURE 3.6 ZXDC has a role in PU.1 protein stabilization: HEK293 cells were 
transfected with the indicated plasmids.  Twenty-four hours post-transfection, cells were 
either untreated or treated with 100 µg/ml cycloheximide for the indicated time points 
and harvested.  Co-transfection of ZXDC was found to have a role in PU.1 protein 
stabilization. 
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ZXDC and ZXDA proteins also interact with the transcriptional repressor, Growth 
factor independent-1 
 Growth factor independent-1 (GFI-1) is a transcriptional repressor that is required 
for granulocyte development (Hock et al., 2003).  GFI-1 was found to antagonize PU.1 
activity to inhibit macrophage differentiation and promote granulocyte development 
(Dahl et al., 2007).  Previous studies by others have shown ZXDC as an interacting 
partner of GFI-1 by yeast-two hybrid assay (Duan et al., 2007).  In order to determine if 
ZXDC and GFI-1 proteins interact in vivo, co-immunoprecipitation assays were 
performed.  Fig. 3.7 demonstrates ZXDC-GFI-1 and ZXDA-GFI-1 interactions.  As a 
negative control for co-IP, HEK293 cells were transfected with only myc-GFI-1 
expression plasmid (Fig. 3.7, lane 3).  Detection of non-specific bands with anti-Flag 
occurred in the absence of either Flag-tagged proteins (Fig. 3.7; panel 2, lane 3).   
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FIGURE 3.7 ZXDC/ZXDA co-immunoprecipitate with GFI-1:  HEK293 cells were 
co-transfected with pCS2-myc-Gfi1 and pFlag-CMV-5a-ZXDC or pCMV-Flag-ZXDA.  
Forty-eight hours post-transfection, the lysate was subjected to co-IP with anti-Flag and 
Western analysis with anti-Myc.  Our results demonstrate that both ZXDC and ZXDA 
proteins interact with GFI-1 (Fig. 3.7, lanes 1 & 2, top panel). Co-IP in the absence of 
either Flag-tagged protein was used as a negative control.  The bottom two panels show 
10% of the lysate taken prior to co-IP as input control. 
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The zinc finger region of ZXDC mediates its interaction with GFI-1 
To map the region of ZXDC necessary for interaction with GFI-1, co-
immunoprecipitation assays were performed in HEK293 cells using ZXDC deletion 
constructs (Fig. 3.8, top panel).  Our results demonstrated that deletion of the N-terminal 
or the C-terminal regions of ZXDC did not affect its interaction with GFI-1 (Fig. 3.8, 
lanes 2 & 3, bottom panel) suggesting that the zinc fingers of ZXDC are necessary to 
associate with GFI-1 protein.  Co-IP of GFI-1 with full-length ZXDC was used as a 
positive control (Fig. 3.8, lane 1, bottom panel), whereas, co-IP in the absence of either 
Flag-tagged proteins was used as a negative control (Fig. 3.8, lane 4, bottom panel)   
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FIGURE 3.8 Zinc fingers of ZXDC mediate ZXDC-GFI-1 interaction. HEK293 cells 
were co-transfected with the indicated plasmids.  Forty-eight hours post-transfection co-
IP was performed with anti-Flag and Western analysis with anti-Myc.  This experiment 
demonstrated that deletion of the N-terminus or the C-terminus of ZXDC does not affect 
its interaction with GFI-1 (lanes 2 &3, bottom panel) suggesting that the zinc fingers of 
ZXDC are necessary to interact with GFI-1.  
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ZXDC represses the transcriptional activity of GFI-1 in a dose-dependent manner 
 We were interested to determine if the ZXDC-GFI-1 interaction has an affect on 
GFI-1 transcriptional activity.  Fig. 3.9 demonstrates that ZXDC represses the 
transcription of a GFI-1 responsive reporter plasmid (Fig. 3.9, top panel) without 
affecting GFI-1 protein expression (Fig. 3.9, bottom panel).  This information is 
important as it leads to further questions such as: Does ZXDC affect GFI-1 recruitment at 
its target promoters and/or expression of known GFI-1 target genes during hematopoietic 
cell differentiation?  Does ZXDC regulate microRNAs miR-21 and miR-196, known 
targets of GFI-1 (Chinavenmeni et al., 2009) that are necessary for normal myelopoiesis?      
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FIGURE 3.9 A. ZXDC repressed Gfi1 transcriptional activity in a dose-dependent 
manner.  HEK293 cells were plated at 2 x 10 5 cells in 24-well plate.  Cells were co-
transfected with 100ng of pT81-Gfi 4X-luciferase and 400ng of pCS2-myc-Gfi1 or 
increasing amounts (10ng and 100ng) of pFlag-CMV-5a-ZXDC plasmids as indicated.  
All transfections included 10ng of phRG-TK-Renilla plasmid to serve as internal control.  
Forty-eight hours after transfection, relative luciferase activity was measured and fold 
increase calculated.  B. Western control showing the expression levels of the indicated 
proteins for the above luciferase experiment. 
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ZXDC is present at the Myc promoter, a known target of GFI-1 
 The interaction of ZXDC with GFI-1 and its repressive affect on GFI-1 
transcriptional activity (Figs. 3.7, 3.9) suggested that it may have a role in GFI-1 
recruitment and/or its activity at its target genes.  Therefore, we wanted to find if ZXDC 
is present along with GFI-1 at the promoters of known GFI-1 target genes. We performed 
chromatin immunoprecipitation experiments in HEK293 cells over-expressed with Flag-
ZXDC and myc-GFI-1 proteins.  Using primers specific for the c-myc or beta-actin 
(negative control) promoters, real-time PCR analysis of the immunoprecipitated DNA 
with anti-Flag, anti-myc or anti-PolII was performed. Our results demonstrated an 
enrichment of ZXDC and GFI-1 proteins along with RNA polymerase II significantly 
over the background (immunoprecipitation with IgG) (Fig. 3.10).  These results also 
eliminate the possibility that the repressive effect of ZXDC on GFI-1 transcriptional 
activity is mediated by somehow sequestering the protein and preventing GFI-1 DNA 
binding. 
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FIGURE 3.10 Chromatin immunoprecipitation (ChIP) analysis in HEK293 cells 
demonstrating the presence of ZXDC along with GFI-1 at the cMyc locus. HEK293 
cells were co-transfected with pFlag-CMV-5a-ZXDC and pCS2-myc-GFI-1.  Forty-eight 
hours post-transfection, ChIP analysis was performed with equal amounts of chromatin 
using antibodies specific for Flag, Myc, PolII or non-specific serum (IgG) followed by 
quantitative Real-time PCR analysis of the eluted DNA with primers specific for the 
promoters of c-Myc or Actin (inset).  Results are the average of three independent 
experiments and error bars represent standard error of the mean (SEM). 
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ZXDC activates Egr-2 promoter activity 
 Microarray analysis by the over expression of ZXDC in HEK293 cells identified 
early growth response-2 (Egr-2) and early growth response-4 (Egr-4) as candidate genes 
that are upregulated (O. Galkin and J.D. Fontes, unpublished observation).  We were 
interested to study this further as early growth response (Egr) proteins were found to have 
a role in monopoiesis and at the same time repress granulocyte-specific genes (Laslo et 
al., 2006).  In addition, Egr-2/Nab-2 and GFI-1 proteins were found to function in a 
counter-antagonistic manner (Laslo et al., 2006).  To determine if ZXDC activates the 
Egr-2 gene at the transcriptional level, we performed reporter assays in HEK293 cells 
transfected with a luciferase reporter driven by the Egr-2 promoter without or with over-
expression of ZXDC.  We observed that over-expression of ZXDC activates Egr-2 
promoter activity modestly, but in a consistent manner.  This modest increase could be 
because there is already endogenous ZXDC available in these cells.  In order to 
determine to which region of the Egr-2 promoter ZXDC binds, we created various 
deletions in the Egr-2 promoter-driving the luciferase reporter gene.  An Egr-2 promoter 
plasmid containing only 50 base pairs upstream of the transcription start site significantly 
reduced the promoter activity, although, the relative activation of this promoter fragment 
by ZXDC was similar to the full-length promoter.  However, further studies are required 
to determine and precisely map ZXDC binding to the Egr-2 promoter region.  
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FIGURE 3.11 ZXDC activates Egr-2 gene transcription. Schematic representation of 
the Egr2 promoter as well as various deletions of the promoter driving the luciferase 
reporter is shown on the left in Fig. 3.11.  HEK293 cells were co-transfected with a 
luciferase reporter driven by Egr-2 promoter (Egr2-L) or with various deletions of the 
Egr2 promoter or pGL3basic (control backbone plasmid) without or with pFlag-CMV-5a-
ZXDC (ZC) along with Renilla reporter plasmid (pRL∆CMV, internal control).  Forty-
eight hours after transfection, Firefly and Renilla luciferase reporter levels were 
measured.  ZXDC showed about a two-fold activation of the EGR2 promoter 
consistently.  Luciferase reporter data in Fig. 3.11 is from three independent experiments 
and error bars represent the standard error of the mean (SEM).  
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Over-expression of ZXDC enhances Egr-2 and Egr-4 mRNA expression levels 
 Since we previously observed modest activation of Egr-2 promoter activity by 
ZXDC (Fig. 3.11), we also wanted to check the transcript levels of early growth response 
genes (Egr-2 and Egr-4).  HEK293 cells were transfected with plasmids that express β-
gal or ZXDC.  After forty-eight hours, total RNA was isolated and the mRNA levels of 
Egr-2, Egr-4, ZXDC and β2 migroglobulin (control) were analyzed by semi-quantitative 
RT-PCR analysis.  The PCR products were analyzed by polyacrylamide gel 
electrophoresis followed by ethidium bromide-stained agarose gels.  This experiment 
demonstrated that ZXDC enhanced Egr-2 and Egr-4 mRNA expression levels when 
ZXDC is over-expressed (Fig. 3.12, compare lanes 1 & 2, top panels).   
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FIGURE 3.12 ZXDC enhanced Egr-2 and Egr-4 mRNA expression levels. 
Expression of EGR2 and EGR-4 transcript levels is enhanced in the presence of ZXDC.  
HEK293 cells are either transfected with pCMV-SPORT6-βgal (stuffer, WT) or pFlag-
CMV-5a-ZXDC (O/E ZXDC).  Forty-eight hours after transfection, total RNA was 
isolated and semi-quatitative RT-PCR analysis was performed using primers specific for 
the indicated transcripts with β2microglobulin as control. The samples were run on 8% 
native polyacrylamide gel followed by staining with ethidium bromide. 
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Discussion 
A complex interplay involving regulatory cross-talk among several cell-type 
specific and stage specific transcription factors and their expression levels are critical for 
the determination of hematopoietic cell fates and lineage decisions (Friedman, 2007; 
Rosenbauer and Tenen, 2007; Laslo et al., 2006; Orkin., 2000).  The transcription factor 
PU.1 belongs to the ets family of transcription factors and is considered the master 
regulator of myelopoiesis, as it plays a key role in the regulation of several myeloid 
specific genes.  For example, it directs hematopoietic stem cells to the lymphoid-myeloid 
progenitor and based on its expression levels and interaction with several key 
transcription factors, is critical for hematopoietic cell-lineage specification.  Preliminary 
studies in our lab suggest that the ZXD family of proteins play a key role in myeloid 
development and differentiation. 
In the studies presented here, we show that ZXDC and ZXDA proteins physically 
interact with PU.1 (Fig. 3.2).  We found that the zinc finger region of ZXDC interacted 
with the N-terminal region of PU.1 containing the activation domain (Figs. 3.3 & 3.4).  
This interaction was found to be functionally significant as ZXDC and ZXDA proteins 
repressed the transcriptional activity of PU.1 by 75% and 50% respectively (Fig. 3.5).  
The interaction of PU.1 with several transcription factors, such as, GATA-1, 
CCAAT/enhancer binding protein α (C/EBPα), Growth factor independent-1 (GFI-1), B 
cell-specific activator protein and Ski was shown to be critical for lineage determination 
and development of hematopoietic cells (Nerlov et al., 2000; Zhang et al., 1999; Reddy et 
al., 2002; Maitra and Atchison, 2000; Dahl et al., 2007; Ueki et al., 2008).  Interestingly, 
all the above proteins inhibit the ability of PU.1 to transactivate its target genes at 
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different stages during hematopoietic differentiation and development.  Such cross-talk 
among hematopoietic regulators is critical for proper cell lineage specification and 
development.  For example, the interaction of GATA proteins with PU.1 that function in 
a cross-antagonistic manner is crucial for hematopoietic stem cells to commit to erythroid 
or myeloid lineages respectively (Zhang et al., 1999).  Given the vital role of such tight 
regulation of PU.1, it is important to study the mechanism and the functional significance 
of the ability of ZXDC and ZXDA to repress PU.1 transactivation during myeloid 
differentiation. 
In our studies, we observed that ZXDC has a role in PU.1 protein stabilization 
(Fig. 3.6).  Previous reports demonstrated that the expression levels of PU.1 are critical 
for hematopoietic cell lineage specification and that deregulation of its expression can 
result in leukemias and lymphomas (Moreau-Gachelin et al., 1988; DeKoter et al., 2000; 
Anderson et al., 2002; Dahl et al., 2003; Cook et al., 2004; Rosenbauer et al., 2004, 2006; 
Huang et al., 2008).  The regulation of PU.1 gene by a proximal promoter (Chen et al., 
1995) and upstream regulatory element (Li et al., 2001; Rosenbauer et al., 2004; Okuno 
et al., 2005) has been well characterized.  Interestingly, PU.1 expression was also found 
to be regulated by sense and antisense RNAs driven by intronic promoters (Ebralidze et 
al., 2008).  Here, we demonstrate that ectopic expression of ZXDC along with PU.1 
resulted in PU.1 protein stabilization in HEK293 cells that do not express endogenous 
PU.1.  At present, we do not know if ZXDC has such a role by inhibiting proteasome 
mediated degradation of PU.1 and if so, identification of the E3 ubiquitin ligase is 
important to understand the molecular mechanism involved.  It is also critical to find if 
signaling mechanism/s are involved in this process.   
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 We have also found that ZXDC interacted with Growth factor independent-1 
(GFI-1), a transcriptional repressor necessary for the granulocyte-monocyte progenitor to 
differentiate along the granulocyte/neutrophil lineage (Dahl et al., 2007).  GFI-1 is a zinc 
finger transcriptional repressor containing an N-terminal SNAG repression domain and a 
C-terminal zinc-finger DNA binding domain that binds to a consensus DNA element 
containing the core sequence AATC (McKay et al., 1996).  GFI-1 promotes 
granulopoiesis by interacting and inhibiting PU.1 mediated transactivation resulting in 
the repression of monocyte-specific genes (Dahl et al., 2007).  Interestingly, ZXDC was 
found to repress the transcriptional activity of GFI-1 in a dose-dependent manner (Fig. 
3.9) suggesting that it may have a role in the lineage specification of granulocyte-
monocyte progenitors.  It is possible that ZXDC sequesters GFI-1 preventing its ability to 
bind DNA to mediate this repression.  However, chromatin immunoprecipitation 
experiments in HEK293 cells demonstrate that ZXDC is present at the c-myc promoter 
(Fig. 3.10) along with GFI-1 that was earlier shown to be a direct target of GFI-1 (Duan 
et al., 2003).  It would be interesting to study further how ZXDC is recruited and how it 
affects recruitment of GFI-1 at its target gene promoters especially following 
differentiation in myeloid progenitors.   
 Several studies demonstrated the critical role of microRNAs in hematopoietic 
differentiation and leukemogenesis (reviewed in Garzon and Croce, 2008).  Recent 
studies have shown an important role for GFI-1 in the regulation of micro-RNAs, miR-21 
(a positive regulator of monopoiesis) and miR-196b (a negative regulator of 
granulopoiesis) for normal myelopoiesis (Chinavenmeni et al., 2009).  In the same report 
it was demonstrated that GFI1-mutant severe congenital neutropenic patient and Gfi-/- 
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mice showed deregulated expression of miR-21 and miR-196b.  Since ZXDC was found 
to affect GFI-1 transcriptional activity, it is important to find if it also affects the 
expression and regulation of miR-21, miR-196b, as well as, several other known GFI-1 
target miRNAs, namely, miR-302b and miR-489 (Chinavenmeni et al., 2009).  It is also 
known that GFI-1 plays an important role in hematopoietic stem cell renewal, given the 
repressive effect of ZXDC on GFI-1, it would be interesting to study how ZXDC 
functions in this scenario. 
 We found that ZXDC activated Egr-2 promoter activity as well as the mRNA 
expression of EGR-2 and EGR-4 (Figs. 3.11 and 3.12).  Interestingly, we found a modest 
increase in the activation of Egr-2 promoter activity, where as, a much higher mRNA 
expression levels by ZXDC in HEK293 cells (Figs. 3.11 and 3.12).  This could be 
explained by the reporter plasmid lacking important sequences necessary for regulation 
of the Egr-2 gene, or perhaps the chromatin structure of the plasmid not mimicking that 
of the endogenous gene, altering its regulation.  Alternatively, it is possible that ZXDC 
may regulate Egr-2 at the post-transcriptional level, perhaps by stabilizing Egr-2 mRNA; 
however, we do not have data at present to demonstrate this.  EGR-2/NAB2 was found to 
be necessary for the transcriptional activation of several monocyte specific genes and also 
for the repression of granulocyte specific genes (Friedman, 2007).  A possible 
mechanistic role for ZXDC in maintaining granulocyte-monocyte cell lineage decisions 
of myeloid progenitors could be that ZXDC by activating Egr-2 promoter activity and/or 
expression may thereby facilitate EGR-2 activity resulting in further activation of 
monocyte specific genes, as well as, for the repression of genes necessary for granulocyte 
development.  Supporting above findings, preliminary FACS results by lentiviral 
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mediated over-expression of ZXDC in HL-60 cells (a pro-myeloblast cell line), 
demonstrated an enhanced level of monocytic cell surface marker, CD14+ (data not 
presented), although, further experiments are necessary to confirm above results.  In 
addition, previous studies demonstrated that GFI-1 and Egr-2/Nab2 function in a cross-
antagonistic manner to maintain granulocyte-monocyte progenitor developmental 
decisions (Laslo et al., 2006). 
 It is interesting how ZXDC functions as a transcriptional activator of certain 
genes (e.g. MHC II, Egr-2) whereas; it repressed transcription of promoters responsive to 
PU.1 and GFI-1.  Protein-protein interaction with co-activators or co-repressors is a 
potential mechanism for such dual regulatory functions.  For example, Egr-1 & Egr-2 are 
zinc finger transcription factors that can activate or repress transcription by binding to a 
consensus DNA sequence (Crosby et al., 1991).  It would be interesting to study how 
ZXDC functions by repressing both PU.1 (pro-monocyte) and GFI-1 (pro-granulocyte) 
activity.  It could be that ZXDC functions at different stages of differentiation.  It is 
possible that ZXDC along with primary lineage determinants (PU.1 and C/EBPα) are 
necessary for fine tuning gene expression at different stages of myeloid differentiation, 
ultimately determining monocyte or granulocyte cell lineage decisions.  There are several 
possibilities for the regulatory role of ZXDC and other members of this family in myeloid 
differentiation and development, however, further studies are needed to confirm the 
molecular mechanisms involved. 
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CHAPTER IV 
DISCUSSION 
 The goal of my dissertation was to demonstrate the functional role of several 
protein-protein interactions amongst two members of the zinc finger, X-linked (ZXD) 
family of proteins, namely, ZXDC and ZXDA that have important roles in the regulation 
of (a) major histocompatibility complex class II (MHC class II) and (b) several myeloid-
specific genes. 
 In chapter II, we demonstrated self- and hetero-association of ZXDC and ZXDA 
proteins and that the zinc fingers of both proteins mediated their interaction.  In addition, 
ZXDC was found to interact with two regulatory factor X (RFX) proteins, namely, RFX5 
and RFX-ANK (RFX with ankyrin repeats), but not RFX-AP (RFX associated protein) 
(Figs. 2.5, 2.6, 2.7) which are components of the MHC class II enhanceosome. 
 The expression of Major histocompatibility complex class II (MHC class II) 
proteins is important for adaptive immune response (Ting and Trowsdale, 2002) and is 
tightly regulated at the transcriptional level (Boss and Jensen, 2003; Van den elsen et al., 
2004).  The transacting factors regulatory factor X (RFX) complex, cyclic AMP response 
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element binding protein (CREB), and nuclear factor Y (NFY) complex bind to a set of 
conserved cis-elements, namely, the W/S, X1, X2, Y boxes (from 5to 3 orientation) 
respectively at the promoters of MHC class II genes (Ting and Trowsdale, 2002; Nekrep 
et al., 2003) The cis- and trans-acting factors result in the formation of a three 
dimensional, higher order nucleoprotein complex called the MHC class II 
enhanceosome (Masternak et al., 2000, Waldburger et al., 2000; Jabrane-Ferrat et al., 
2003).  However, these genes are turned on or off based on the presence or absence 
of the key transcriptional cofactor, the class II transactivator (CIITA; Steimle et al., 1993; 
Reith and Mach, 2001).  Hence, many studies focused on the mechanisms of CIITA 
mediated transcriptional activation of MHC class II genes.   
 Studies in our lab identified a novel CIITA binding protein, zinc finger, X-linked, 
duplicated family member C (ZXDC; Al-Kandari et al., 2000a).  ZXDC is so named 
because of its amino acid sequence homology with two other zinc finger proteins, 
namely, zinc finger, X-linked, duplicated family members A and B (ZXDA and ZXDB 
respectively) (Al-Kandari et al., 2007a).  Each of the ZXDC and ZXDA proteins contain ten 
C2H2 zinc fingers and transcription activation domain.  The ZXDC protein, in addition, has a C-
terminal region that is necessary to interact with CIITA (Al-Kandari et al., 2007a).  Recent 
reports demonstrated that ZXDC activated MHC class II and MHC class I gene 
transcription, whereas, knock-down of ZXDC by siRNA in HEK293 cells showed 
significant reduction of MHC class II gene expression (Al-Kandari et al., 2007a).  
Although ZXDA lacked the CIITA binding region, it showed a synergistic effect in the 
transcriptional activation of MHC class II genes by CIITA (Al-Kandari et al., 2007b) 
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suggesting that interactions of ZXDA with other proteins may provide a role for such 
regulatory mechanism. 
 At the time I started in the lab, we wanted to address the mechanism of ZXDC 
mediated activation of MHC class II gene transcription.  The ZXDC and ZXDA proteins 
each contained ten multiple adjacent C2H2 type zinc fingers.  The role of C2H2 zinc 
fingers is in macromolecular interactions, including protein-DNA, protein-RNA and 
protein-protein interactions (McCarty et al., 2003; Sun et al., 1996; Hata et al., 2000; Tsai 
et al., 1998; Wang et al., 2001; Cassiday et al., 2002).  We were able to demonstrate self- 
and hetero-association of ZXDC and ZXDA proteins and that the zinc fingers of both 
proteins mediate their interaction.  We were not able to identify which zinc fingers of 
ZXDC and ZXDA mediate these protein-protein interactions, as deletions of some zinc 
fingers resulted in destabilization of the protein (data not presented).  Interestingly, in 
vitro protein-protein interaction assays demonstrated that only a hetero-complex of 
ZXDC and ZXDA but neither protein by itself was sufficient to interact with CIITA (Al-
Kandari et al., 2007b).  Supporting this, knock-down of ZXDC or ZXDA resulted in 
significant repression of MHC class II gene expression by CIITA.  This decrease was not 
significantly different from knock-down of both ZXDC and ZXDA suggesting for the 
requirement of both proteins for MHC class II gene regulation (Al-kandari et al., 2007b).  
The ability of ZXDC and ZXDA proteins to associate with themselves as well as with 
each other gives rise to complexes with different combinations of functionally active 
protein-protein (ZXDC-ZXDA) or protein-DNA interactions.  For the latter, it is very 
important that the nucleotide sequences to which ZXDC binds be identified.      
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 ZXDC was found to be present at the MHC class II promoter in Raji cells, a B 
cell line that constitutively expresses MHC class II proteins and in HeLa cells prior to 
and after IFNγ treatment (Al-Kandari et al., 2007a, 2007b).  Given the important role of 
C2H2 type zinc fingers in DNA binding, we tried extensively to demonstrate direct 
binding of ZXDC to MHC class II promoter region, especially the W box, but we could 
not find.  Dr. Srikarthika Jambunathan in our lab identified that ZXDC preferentially 
binds to a purine rich sequence, AGGGT/A using an in vitro screening assay.  However, 
further studies are necessary to investigate the aspects of ZXDC-DNA interaction. 
Although nucleic acid binding by zinc fingers was the primary focus for many 
years, more recently the importance of protein-protein interactions mediated by zinc 
fingers has come to the fore (Gamsjaeger et al., 2007; Brayer et al., 2008a, 2008b).  Since 
chromatin immunoprecipitation experiments demonstrated that ZXDC is present at MHC 
class II promoters, the most likely interpretation is that ZXDC is recruited to the MHC 
class II promoters indirectly, via protein-protein interactions.  Our data support this 
notion.  We were able to demonstrate that ZXDC selectively interacted with components 
of MHC class II enhanceosome, specifically, CIITA (Al kandari et al., 2007a), RFX5 
(Fig. 2.5), RFXANK (Fig. 2.6) and possibly other components of the MHC class II 
enhanceosome.  The results presented here along with previous findings suggest a 
possible role for ZXDC-ZXDA complex in stabilizing MHC II enhanceosome complex 
suggesting a mechanism of MHC class II gene activation. 
The interaction of ZXDC with the components of the MHC class II 
enhanceosome could be a possible mechanism for the recruitment of ZXDC along with 
ZXDA at the MHC class II promoter.  ZXDA, however, was not found to interact with 
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RFX5 and neither was ZXDC protein capable of associating with RFX-AP suggesting 
specificity for these protein-protein interactions.  Mechanistically, an unanswered 
question is whether ZXDC is recruited to the promoter as a hetero-dimer along with  
ZXDA or if ZXDA is recruited later during gene activation.  Similarly, if further studies 
could demonstrate the interaction of ZXDC with one or more other components of the 
MHC class II enhanceosome, namely, CREB or proteins constituting the NFY complex, 
it would strengthen our model of ZXDC stabilizing the MHC II enhanceosome.  The 
assembly of transcription factors requires precise positioning of the DNA binding sites to 
form the nucleoprotein complex, enhanceosome.  Even in the case of MHC class II 
enhanceosome, exact spacing and orientation of the conserved W/S, X1, X2 and Y 
promoter elements is critical for the recruitment and binding of the transacting factors 
(RFX complex, CREB, NFY complex) and the entire nucleoprotein complex functions as 
a single unit to regulate MHC class II gene transcription (Jabrane-Ferrat et al., 1996, 
2002; Nekrep et al., 2000; Hake et al., 2000; Masternak et al., 2000; Zhu et al., 2000).  
There are several mechanisms of enhanceosome dependent transcriptional synergy.  The 
individual protein-protein or protein-DNA interactions may be weak, but multiple co-
operative interactions result in the formation of a powerful transcriptional activation 
machine as a result of enhanced stability of the complex (Merika and Thanos, 2001).  It is 
also possible that the three-dimensional structure of the enhanceosome creates optimal 
interaction surface of the activation domains of CIITA and ZXDC proteins to interact 
with the general transcription machinery or chromatin remodeling factors for gene 
activation.  An example of such a mechanism is found at α1-AT promoter between HNF-
1α and HNF-4α which recruits TFIID and CBP/PCAF, hBrm respectively (Cosma et al., 
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2002).  Some other examples of eukaryotic genes regulated by enhanceosomes include 
interferon-β gene, interleukin-6 gene, interleukin-2 receptor α chain gene (reviewed in 
Panne, 2008; Carey, 1998; Merika and Thanos, 2001).  
The mechanism of ZXDC-ZXDA mediated activation of MHC II genes is not 
very clear at present.  A probable mechanistic role for this hetero-complex in MHC II 
gene activation is through interaction with CIITA, RFX5 and RFXANK resulting in 
stablilizing the MHC II enhanceosome.  Further studies demonstrating protein-protein 
interactions of ZXDC or ZXDA with any other components of the MHC II 
enhanceosome, namely, CREB protein, components of the NFY complex or chromatin 
remodeling factors will further strenghthen this model.  However, further study is 
necessary to know the exact regulatory mechanism by which the ZXDC-ZXDA complex 
activates MHC class II gene transcription.    
 In chapter III, we found that ZXDC interacted with two hematopoietic 
transcription factors, namely, purine rich box-1 (PU.1) protein and growth factor 
independent-1 (GFI-1).  This interaction was found to have a functional role as ZXDC 
repressed the transcriptional activities of PU.1 and GFI-1 proteins in reporter assays.  
Chromatin immunoprecipitation experiments demonstrated that ZXDC is present along 
with GFI-1 at the Myc locus, a known target of GFI-1.  Our studies also revealed that 
ZXDC activated the transcription of Egr-2 gene whose expression is related with the 
activation of monocytic target genes and repression of granulocytic target genes.  We also 
found that ZXDC enhanced PU.1 protein expression, whose levels are important for 
determining hematopoietic cell lineage decisions.  Our studies probably demonstrate that 
ZXDC may affect the transcriptional activities and/or recruitment of PU.1 and GFI-1 at 
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their target gene promoters especially following differentiation of myeloid progenitors.  
In addition, it is also possible that ZXDC by activating Egr-2 transcription and expression 
while repressing GFI-1 transcriptional activity may have a role in fine tuning 
differentiation of myeloid progenitors into monocytic lineage.  However, further study is 
necessary to confirm the regulatory role of ZXDC in monopoiesis.     
 The interplay and cross-talk among several ubiquitous and cell-type specific 
transcription factors and their relative expression levels are important to regulate target 
genes necessary for cell fate and lineage decisions (Friedman, 2007; Rosenbauer and 
Tenen, 2007; Laslo et al., 2006; Orkin., 2000).  Our results demonstrated interaction of 
ZXDC and ZXDA proteins with two hematopoietic transcription factors, namely, purine 
box binding protein, PU.1 (Fig. 3.2) and growth factor independent-1 (GFI-1; Fig. 3.7).  
Purine-rich box-1 (PU.1) protein belongs to the Ets family of transcription factors and is 
encoded by the spleen focus forming virus proviral integration site-1 (sfpi1) gene 
(McKercher et al., 1996; Dahl et al., 2003; Laslo et al., 2006; Huang et al., 2007a; Yang 
et al., 2000; Reddy et al., 2002; Rekhtman et al., 1999, 2003; DeKoter and Singh, 2000).  
PU.1 plays a central role in hematopoieis as it is necessary for myeloid differentiation, B 
and T cell development, hematopoietic stem cell maintenance and erythropoiesis 
(Kastner & Chan, 2008).  GFI-1 is a zinc finger transcriptional repressor that is 
indispensible for neutrophil differentiation and development (Hock et al., 2003).  It 
contains an N-terminal SNAG repression domain and six C-terminal zinc fingers 
necessary for DNA binding (Grimes et al., 1996; Zweidler-Mckay et al., 1996).  
 Our studies revealed that ZXDC and ZXDA proteins interacted with the 
hematopoietic transcription factor PU.1 (Fig. 3.2).  The interaction of ZXDC or ZXDA 
124 
proteins with PU.1 resulted in repression of PU.1 transcriptional activation by about 75% 
and 50% respectively (Fig. 3.5).  The zinc finger domain of ZXDC was found to be 
necessary to mediate interaction with the N-terminal region of PU.1 containing the 
activation domain (Figs. 3.3 & 3.4).  There are several examples of transcription factors 
that interact with distinct domains of the PU.1 protein.  Some of these examples include 
GATA binding protein-1 (GATA-1), CCAAT/enhancer binding protein α (C/EBPα), 
growth factor independent-1 (GFI-1), B-cell specific activator protein (BSAP) (Nerlov et 
al., 2000; Zhang et al., 1999; Reddy et al., 2002; Maitra and Atchison, 2000; Dahl et al., 
2007; Ueki et al., 2008).  The interaction of PU.1 with these transcription factors at 
different stages of hematopoietic differentiation was found to be critical for cell fate/ 
lineage determination and development.  It is important to note that each of the 
transcription factors mentioned above interacts with and represses PU.1 transcriptional 
activation at specific stages during differentiation.  Such interplay among transcription 
factors often has several regulatory roles.  For example, GATA (GATA-1 & GATA-2) 
and PU.1 proteins function in a cross-antagonistic manner for the determination of 
erythroid or myeloid cell lineages respectively (Zhang et al., 1999).  Given the critical 
role for interacting partners of PU.1, it is important to address the mechanism and the 
functional significance of the ability of ZXDC and ZXDA proteins to repress PU.1 
transactivation during myeloid differentiation.  The ability of both ZXDC and ZXDA 
proteins to interact with and repress PU.1 transactivation ability lead us to asking further 
questions: Do they function cooperatively as a homo- or hetero-complex similar to what 
we saw with interaction with the cofactor CIITA (Al-Kandari et al., 2007b) or if they can 
compensate for each other functionally.  Although, ZXDC and ZXDA proteins share 
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significant amino acid sequence homology, there are regions that are very distinct for 
each of them (Al-Kandari et al., 2007b) and hence, it is important to address this. 
We have found that ZXDC stabilized PU.1 protein expression levels (Fig. 3.6).  
This is an important observation since PU.1 protein expression levels are correlated to 
specifying hematopoietic cell lineage decisions and that deregulation resulting in even 
slight decrease in its expression levels can result in leukemia (Moreau-Gachelin et al., 
1988; DeKoter et al., 2000; Anderson et al., 2002; Dahl et al., 2003; Cook et al., 2004; 
Rosenbauer et al., 2004, 2006; Huang et al., 2008).  At the transcriptional level, the 
expression of PU.1 is regulated by a proximal promoter (Chen et al., 1995) and an 
upstream regulatory element located 14 kilo bases upstream of the transcription start site 
(Li et al., 2001; Rosenbauer et al., 2004; Okuno et al., 2005).  At the post-transcriptional 
level, PU.1 expression is regulated by sense and anti-sense RNAs driven by intronic 
promoters (Ebralidze et al., 2008).  In our studies, we found that over-expression of 
ZXDC resulted in stabilizing PU.1 protein expression.  We found less than two-fold 
increase in PU.1 mRNA levels upon ZXDC over-expression (data not presented).  At 
present, it is not very clear the mechanism of ZXDC mediated PU.1 protein stabilization.  
It is possible that ZXDC has such a role by inhibiting PU.1 degradation by the 
proteasome mediated pathway.  However, further study is necessary to address this.  
 Growth factor independent-1 is a zinc finger transcriptional repressor that is 
necessary for granulocyte differentiation.  GFI-1 inhibits monocytic genes in 
granulocytes by direct interaction with PU.1 and inhibiting its transcriptional activation.  
Studies by others also identified ZXDC as one of Growth factor independent-1 
interacting partners by yeast-two-hybrid assay (Duan et al., 2007).  Our results confirmed 
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ZXDC-GFI-1 interaction and found that ZXDC repressed GFI-1 transcriptional activity 
in a dose-dependent manner.  At present, we do not know the mechanism of ZXDC 
mediated repression of GFI-1 transcriptional activity.  Since ZXDC was first identified as 
an interacting partner of GFI-1 in a yeast-two hybrid screen using the C-terminal DNA 
binding zinc fingers of GFI-1 as a bait, it is possible that ZXDC may sequester GFI-1 by 
binding to its C-terminal zinc fingers thereby preventing GFI-1 DNA binding.  However, 
chromatin immunoprecipitation experiments in HEK293 cells revealed that ZXDC is 
present along with GFI-1 at the Myc locus, a known target of GFI-1.  However, further 
study is necessary to address if ZXDC affects the transcriptional activity or recruitment 
of GFI-1 at its target gene promoters during differentiation of myeloid progenitors.  
Importantly, GFI-1 was found to cooperate with an Ets family transcription factor, ETS1 
in the repression of Bax which is a pro-apoptotic gene (Nakazawa et al., 2007).   Since 
ZXDC was found to repress GFI-1 transcriptional activity and since both proteins are 
present at the promoter of Myc, which is involved in cell cycle regulation, it would be 
interesting to find if ZXDC affects apoptosis.  It is also important to address if the 
interaction of ZXDA with GFI-1 is functionally significant.   
 Recent studies highlight an important role for microRNAs in hematopoiesis 
(reviewed in Garzon and Croce, 2008).  GFI-1 was found to play an important role in the 
regulated expression of microRNAs, miR-21 and miR-196b that is necessary for normal 
hematopoiesis (Chinavenmeni et al., 2009).  In the same study it was revealed that a 
mutation in the GFI1 gene described in a patient with severe congenital neutropenic 
patient and Gfi-/- mice showed deregulated expression of miR-21 and miR-196b.  Based 
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on the results presented in chapter III and in the paragraph above, it is important to find if 
ZXDC regulates any of GFI-1 target micro-RNAs. 
 Microarray analysis identified Egr-2 and Egr-4 as candidate genes that are 
upregulated upon ZXDC over expression in HEK293 cells (Galkin, O., Fontes, J.D., 
unpublished observation).  Further studies confirmed that ZXDC activates the 
transcription and expression of Egr-2 gene (Figs. 3.11 and 3.12).  To confirm direct 
regulation of Egr-2 gene by ZXDC, it is important to find the effect of ZXDC knock-
down on Egr-2 expression.  We expect to see a decrease in the promoter activity and 
expression of Egr-2 following knock-down of endogenous ZXDC.  Alternatively, it is 
also possible that the ZXDA protein can compensate in which case we may not see a 
significant decrease in Egr-2 expression levels. 
 A complex of EGR-2 and the transcriptional co-regulator NAB2 was found to be 
necessary for the transcriptional activation of several monocyte specific genes and also 
for the repression of granulocyte specific genes (Laslo et al., 2006).  A possible 
mechanism of ZXDC in granulocyte-monocyte cell lineage decision could be by 
activation of Egr-2 expression, resulting in transcription of monocyte-specific genes, and 
repression of granulocyte-specific genes.  Supporting this model, preliminary data for 
over-expression of ZXDC in HL-60 cells (a pro-myeloblast cell line), demonstrated an 
enhanced level of monocytic cell surface marker (CD14) expression (data not presented). 
Further experiments are necessary to confirm these preliminary data.   
 In addition, previous studies demonstrated that GFI-1 and Egr-2/Nab2 function in 
a cross-antagonistic manner to maintain granulocyte-monocyte progenitor developmental 
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decisions (Laslo et al., 2006).  Although, GFI-1 was found to regulate its target genes by 
direct DNA binding, a recent report demonstrated that GFI-1 is recruited through Miz-1 
to repress CDKN2B gene that encodes the cyclin dependent kinase inhibitor (CDKI), 
P15INK4B (Basu et al., 2009).  Interestingly, CDKN2B was found to be a gene that was 
activated 3.5X when ZXDC was over-expressed in HEK293 cells as demonstrated by 
microarray analysis (Galkin, O and Fontes, J.D., data not presented).  Potentially, a 
similar mechanism exists for GFI-1 repressing ZXDC activation of Egr-2.   
 Taken together, our studies demonstrate a dual regulatory role for ZXDC.  We 
found that ZXDC functions in the transcriptional activation of MHC II and Egr-2 genes, 
whereas, functions in the transcriptional repression of promoters responsive to PU.1 and 
GFI-1.  There are many examples of transcription factors that have such dual regulatory 
roles.  For example, Egr-1 & Egr-2 are transcription factors whose expression is 
associated with the activation of monocyte target genes and repression of granulocyte 
target genes thus promoting monocyte development and differentiation.  Additional 
examples of such dichotomous transcriptional regulators include WT1 which can be 
converted from an activator to a repressor by interaction with a soluble nuclear factor, 
MDM2 which functions as a co repressor of p53 function, but as a coactivator for the 
function of E2F, the nuclear hormone receptors that are converted from transcriptional 
repressors to activators upon interaction with ligand (Holstege et al., 1998; Wang et al., 
1995; McKay et al., 1999; Martin et al., 1995).  Studies have demonstrated an important 
role for GFI-1 (Hock et al., 2004; Zeng et al., 2004; reviewed in Duan and Horwitz, 
2005) and PU.1 (reviewed in Kastner and Chan, 2008) in hematopoietic stem cell 
129 
maintenance and hence it is important to address if ZXDC has a functional role in this 
scenario.  
Our studies probably demonstrate that ZXDC by activating Egr-2 gene 
transcription and expression, while simultaneously repressing GFI-1 transcriptional 
activity may favor myeloid progenitors to differentiate along the monocytic lineage, 
while simultaneously repressing granulocyte target genes.  It is also possible that ZXDC 
has a functional role in fine tuning differentiation of myeloid progenitors by interacting 
with the primary cell fate determinants, PU.1 and C/EBPα at different stages of 
hematopoietic differentiation.  In this regard it is important to check if ZXDC interacts 
with C/EBPα for fine tuning differentiation of myeloid progenitors into macrophage or 
granulocyte lineages (reviewed in Rosenbauer and Tenen, 2007).  Further study is 
necessary to confirm the regulatory roles of ZXDC and other members of the ZXD 
family proteins in hematopoiesis.  
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